

'Apo' Aporosa, S. 2015. "The New Kava User: Diasporic Identity Formation in Reverse." *New Zealand Sociology* 30 (4): 58–77.

(Apo) Aporosa, S., and Matt Tomlinson. 2014. "Kava Hangover and Gold-Standard Science." *Anthropologica* 56 (1): 163–75. <https://doi.org/10.1353/ant.2014.0014>.

Abbs, Peter d', and Chris Burns. 1997. "Draft Report on Inquiry into the Issue of Kava Regulation." *Darwin: Menzies School of Health Research*.
https://www.parliament.nt.gov.au/__data/assets/pdf_file/0006/368025/kava.pdf.

Abdel Jaleel, Gehad A., Dalia O. Saleh, and Sally A. El-Awdan. 2013. "Antihyperglycaemic Effect of Kava Kava (piper Methysticum) in Streptozotocin- Induced Diabetic Rats." *Der Pharmacia Lettre* 5 (5): 104–10.

Abu, Nadiah, M. Nadeem Akhtar, Swee Keong Yeap, Kian Lam Lim, Wan Yong Ho, Aimi Jamil Zulfadli, Abdul Rahman Omar, Mohd Roslan Sulaiman, Mohd Puad Abdullah, and Noorjahan Banu Alitheen. 2014. "Flavokawain A Induces Apoptosis in MCF-7 and MDA-MB231 and Inhibits the Metastatic Process in Vitro." *PloS One* 9 (10): e105244. <https://doi.org/10.1371/journal.pone.0105244>.

Abu, Nadiah, Wan Yong Ho, Swee Keong Yeap, M. Nadeem Akhtar, Mohd Puad Abdullah, Abdul Rahman Omar, and Noorjahan Banu Alitheen. 2013. "The Flavokawains: Uprising Medicinal Chalcones." *Cancer Cell International* 13 (1): 102. <https://doi.org/10.1186/1475-2867-13-102>.

Abu, Nadiah, Nurul Elyani Mohamed, Swee Keong Yeap, Kian Lam Lim, M. Nadeem Akhtar, Aimi Jamil Zulfadli, Beh Boon Kee, Mohd Puad Abdullah, Abdul Rahman Omar, and Noorjahan Banu Alitheen. 2015. "In Vivo Antitumor and Antimetastatic Effects of Flavokawain B in 4T1 Breast Cancer Cell-Challenged Mice." *Drug Design, Development and Therapy* 9 (March): 1401–17.
<https://doi.org/10.2147/DDDT.S67976>.

Abu, Nadiah, Nurul Elyani Mohameda, Nirosha Tangarajoo, Swee Keong Yeap, M. Nadeem Akhtar, Mohd Puad Abdullah, Abdul Rahman Omar, and Noorjahan Banu Alitheen. 2015. "In Vitro Toxicity and in Vivo Immunomodulatory Effects of Flavokawain A and Flavokawain B in Balb/C Mice." *Natural Product Communications* 10 (7): 1199–1202. <https://doi.org/10.1177/1934578X1501000716>.

Al-Achi, Antoine. 2015. "Is Kava Safe to Be Used by the Public?" *Clinical Pharmacology & Biopharmaceutics* 04 (04). <https://doi.org/10.4172/2167-065x.1000e120>.

Almeida, J. C., and E. W. Grimsley. 1996. "Coma from the Health Food Store: Interaction between Kava and Alprazolam." *Annals of Internal Medicine* 125 (11): 940–41. <https://doi.org/10.7326/0003-4819-125-11-199612010-00023>.

Ambrose, W. 1991. "Manus, Mortars and the Kava Concoction."
<https://www.semanticscholar.org/paper/097e6b89e9b9b7cd01a76f4f8bc07e300fbca9ca>.

Amdidouche-Hussain'I, Didja, and Joel Levesque. 1997. "Selection of Kavalactones by Complexation of Kava Extract with Cyclodextrins." *Drug Development and Industrial Pharmacy* 23 (12): 1223–26. <https://doi.org/10.3109/03639049709146161>.

Anke, J., S. Fu, and I. Ramzan. 2006. "Kavalactones Fail to Inhibit Alcohol Dehydrogenase in Vitro." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 13 (3): 192–95. <https://doi.org/10.1016/j.phymed.2004.07.005>.

Anke, Jennifer, and Iqbal Ramzan. 2004a. "Pharmacokinetic and Pharmacodynamic Drug Interactions with Kava (Piper Methysticum Forst. F.)." *Journal of Ethnopharmacology* 93 (2-3): 153–60. <https://doi.org/10.1016/j.jep.2004.04.009>.

Anke, Jennifer, and Iqbal Ramzan. 2004b. "Kava Hepatotoxicity: Are We Any Closer to the Truth?" *Planta Medica* 70: 193–96. <https://doi.org/10.1055/s-2004-815533>.

Apo Aporosa, S. 2011. "Aporosa S. 'Apo' - 2011 - Is Kava Alcohol The Myths and the Facts.pdf." *Pacific Health Dialog* 17 (1): 157–64. <https://pubmed.ncbi.nlm.nih.gov/23008981/>.

Apo Aporosa, S. 2015. "Yaqona (kava) as a Symbol of Cultural Identity." S. 'Aporosa.

Aporosa, A. S. 2019. "Kava, the Devil, and the Snake: Pentecostal Iconoclasm in Contemporary Fiji." *University of Auckland*.

Aporosa, Apo. 2019. "Australia's Discussion of Kava Imports Reflects Lack of Cultural Understanding." *The Conversation*, June 9, 2019. <http://theconversation.com/australias-discussion-of-kava-imports-reflects-lack-of-cultural-understanding-115662>.

Aporosa, Apo S., Martin Atkins, and Richard Brunton. 2020. "Kava Drinking in Traditional Settings: Towards Understanding Effects on Cognitive Function." *Human Psychopharmacology* 35 (2): e2725. <https://doi.org/10.1002/hup.2725>.

Aporosa, S. 2017a. "Kava: Untangling Fact from Fiction." In *KAVA: A Workshop for Kava Researchers and Enthusiasts: Anthropology and Pacific Studies Seminar Series*. researchcommons.waikato.ac.nz. <https://researchcommons.waikato.ac.nz/handle/10289/11047>.

———. 2017b. "Understanding Cognitive Functions Related to Driving Following Kava (Piper Methysticum) Use at Traditional Consumption Volumes." In *British Association for Psychopharmacology Conference*, A84–A84. SAGE Publications. <https://researchcommons.waikato.ac.nz/handle/10289/11307>.

———. 2018. "Improving Road Safety and Health: Understanding Kava's Impact on Driver Fitness."

University of Waikato. <https://researchcommons.waikato.ac.nz/handle/10289/12947>.

———. 2019. "Cognitive Functions Associated with Consumption of Traditional Volumes of Kava (Piper Methysticum): A Feasibility Study." In *British Association for Psychopharmacology*.
researchcommons.waikato.ac.nz. <https://researchcommons.waikato.ac.nz/handle/10289/12780>.

Aporosa, S. Apo. 2019a. "Kava and Ethno-Cultural Identity in Oceania." In *The Palgrave Handbook of Ethnicity*, edited by Steven Ratuva, 1–15. Singapore: Springer Singapore. https://doi.org/10.1007/978-981-13-0242-8_134-1.

———. 2019b. "De-Mythologizing and Re-Branding of Kava as the New 'world Drug' of Choice." *Drug Science, Policy and Law* 5 (January): 2050324519876131. <https://doi.org/10.1177/2050324519876131>.

Aporosa, S. Apo, Martin Atkins, and Jess N. Leov. 2021. "Decolonising Quantitative Methods within a Pacific Research Space to Explore Cognitive Effects Following Kava Use." *Journal of Interdisciplinary Research* 5 (1). <https://doi.org/10.26021/10642>.

Aporosa, S. 'apo'. 2014. "YAQONA (KAVA) AND EDUCATION IN FIJI: INVESTIGATING 'CULTURAL COMPLEXITIES' FROM A POST-DEVELOPMENT PERSPECTIVE."

Aporosa, S., and Jacinta Forde. 2019. "Māori and Kava: New Drug Fashion or Re-Engagement With 'kawa'?" *Pacific Dynamics* 3 (1): 72–85.
<https://researchcommons.waikato.ac.nz/handle/10289/12952>.

Aporosa, S. G. 2008. *Yaqona (Kava) and Education in Fiji: A Clash of Cultures?* VDM Verlag.

Ashraf-Khorassani, M., L. T. Taylor, and M. Martin. 1999. "Supercritical Fluid Extraction of Kava Lactones from Kava Root and Their Separation via Supercritical Fluid Chromatography." *Chromatographia* 50: 287–92. <https://doi.org/10.1007/BF02490830>.

Aughton, Harvey. 2020. "Kava and Balance: The Effects of Traditionally Influenced Kava Consumption on Human Physiology." The University of Waikato.
<https://researchcommons.waikato.ac.nz/handle/10289/14110>.

Backhaul, Cord, and Josef Kriegelstein. 1992. "Extract of Kava (Piper Methysticum) and Its Methysticin Constituents Protect Brain Tissue against Ischemic Damage in Rodents." *European Journal of Pharmacology* 215: 265–269.

Backle, Marlène, Perihan Ekici, Günther Leupold, and Harun Parlar. 2003. "Quantitative Elimination of Flavokavines A and B from Kava Kava (Piper Methysticum G. Forst) by Isoelectric Focused Adsorptive Bubble Separation." *Die Naturwissenschaften* 90 (8): 366–69. <https://doi.org/10.1007/s00114-003-0440-5>.

Baker, Jonathan D. 2011. "Tradition and Toxicity: Evidential Cultures in the Kava Safety Debate." *Social Studies of Science* 41 (3): 361–84. <https://doi.org/10.1177/0306312710395341>.

———. 2012. "Pills, Potions, Products: Kava's Transformations in New and Nontraditional Contexts." *The Contemporary Pacific* 24 (2): 233–65. <https://doi.org/10.1353/cp.2012.0026>.

Balick, Michael J., and Roberta Lee. 2002. "Traditional Use of Sakau (kava) in Pohnpei: Lessons for Integrative Medicine." *Alternative Therapies in Health and Medicine* 8 (4): 96–98. <https://www.ncbi.nlm.nih.gov/pubmed/12126179>.

Balick, Michael J & Lee, Robert A. 2009. "The Sacred Root." In *Ethnobotany of Pohnpei*, 165–203. University of Hawaii Press.

Barguil, Yann, Erwan Choblet, Sébastien Warter, and Mohammed Nour. 2013. "Kava Ichthyosis: A Nitric Oxide Synthase Inhibition?" *Annales de Toxicologie Analytique* 25 (4): 165–68. <https://doi.org/10.1051/ata/2014001>.

Barnes, Joanne, Linda A. Anderson, and J. D. Phillipson. 2007. "Kava - Overview." In *Herbal Medicines*, 389–402. 3rd Ed. Grayslake, IL: Pharmaceutical Press.

Bauer, Rudolf, Brigitte & Kopp, and A. Nahrstedt. 2003. "Relevant Hepatotoxic Effects of Kava Still Need to Be Proven: A Statement of the Society for Medicinal Plant Research." *Planta Medica* 69 (11): 971–72. <https://doi.org/10.1055/s-2003-45140>.

Baum, S. S., R. Hill, and H. Rommelspacher. 1998. "Effect of Kava Extract and Individual Kavapyrones on Neurotransmitter Levels in the Nucleus Accumbens of Rats." *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 22 (7): 1105–20. [https://doi.org/10.1016/s0278-5846\(98\)00062-1](https://doi.org/10.1016/s0278-5846(98)00062-1).

Becker, Matheus William, Emerson Matheus Silva Lourençone, Alexandre Formighieri De Mello, Aline Branco, Edison Moraes Rodrigues Filho, Celso Ronaldo Blatt, Carlos Augusto Mallmann, Maurício Schneider, Rita Catalina Aquino Caregnato, and Carine Raquel Blatt. 2019. "Liver Transplantation and the Use of KAVA: Case Report." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 56 (March): 21–26. <https://doi.org/10.1016/j.phymed.2018.08.011>.

Behl, Mamta, Abraham Nyska, Rajendra S. Chhabra, Gregory S. Travlos, Laurene M. Fomby, Barney R. Sparrow, Milton R. Hejtmancik, and Po C. Chan. 2011. "Liver Toxicity and Carcinogenicity in F344/N Rats and B6C3F1 Mice Exposed to Kava Kava." *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association* 49 (11): 2820–29. <https://doi.org/10.1016/j.fct.2011.07.067>.

Berry, Jonna, Ashley Gilbert, and Justin Grodnitzky. 2019. "Cases of Kava Impairment in Iowa Drivers."

Journal of Forensic Sciences 64 (6): 1943–49. <https://doi.org/10.1111/1556-4029.14130>.

BfArM. 2002. “Kava Removal.” http://lrd.spc.int/ahp-publications/doc_download/578-gr-cis-bfarm-kava-removal.

Bian, Tengfei, Pedro Corral, Yuzhi Wang, Jordy Botello, Rick Kingston, Tyler Daniels, Ramzi G. Salloum, et al. 2020. “Kava as a Clinical Nutrient: Promises and Challenges.” *Nutrients* 12 (10). <https://doi.org/10.3390/nu12103044>.

Bilia, Anna Rita, Sandra Gallon, and Franco F. Vincieri. 2002. “Kava-Kava and Anxiety: Growing Knowledge about the Efficacy and Safety.” *Life Sciences* 70 (22): 2581–97. [https://doi.org/10.1016/s0024-3205\(02\)01555-2](https://doi.org/10.1016/s0024-3205(02)01555-2).

Bilia, Anna Rita, Luca Scalise, Maria Camilla Bergonzi, and Franco F. Vincieri. 2004. “Analysis of Kavalactones from Piper Methysticum (kava-Kava).” *Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences* 812 (1-2): 203–14. <https://doi.org/10.1016/j.jchromb.2004.07.038>.

Bird, Gail. 2016. “Import Restrictions: Kava and Khat.” The Office of Drug Control. December 7, 2016. <https://www.odc.gov.au/import-restrictions-kava-and-khat>.

Boerner, R. J. 2001. “Kava Kava in the Treatment of Generalized Anxiety Disorder, Simple Phobia and Specific Social Phobia.” *Phytotherapy Research: PTR* 15 (7): 646–47. <https://doi.org/10.1002/ptr.1006>.

Boerner, R. J., H. Sommer, W. Berger, U. Kuhn, U. Schmidt, and M. Mannel. 2003. “Kava-Kava Extract LI 150 Is as Effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-Week Randomized, Double-Blind Multi-Centre Clinical Trial in 129 out-Patients.” *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 10 Suppl 4: 38–49. <https://doi.org/10.1078/1433-187x-00309>.

Boerner, Reinhard J., and Stephan Klement. 2004. “Attenuation of Neuroleptic-Induced Extrapyrimal Side Effects by Kava Special Extract WS 1490.” *Wiener Medizinische Wochenschrift* 154 (21-22): 508–10. <https://doi.org/10.1007/s10354-004-0115-7>.

Boon, Heather S., and Albert H. C. Wong. 2003. “Kava: A Test Case for Canada’s New Approach to Natural Health Products.” *CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne* 169 (11): 1163–64. <https://www.cmaj.ca/content/169/11/1163>.

Boonen, G., B. Ferger, K. Kuschinsky, and H. Häberleinl. 1998. “In Vivo Effects of the Kavapyrones (+)-Dihydromethysticin And(±)-Kavain on Dopamine, 3,4-Dihydroxyphenylacetic Acid, Serotonin and 5-Hydroxyindoleacetic Acid Levels in Striatal and Cortical Brain Regions.” *Planta Medica* 64: 507–10.

Boonen, Georg, and Hanns Hberlein. 1998. "Influence of Genuine Kavapyrone Enantiomerson the GABAA Binding Site." *Planta Medica* 64: 504–6.

Botello, Jordy F., Pedro Corral, Tengfei Bian, and Chengguo Xing. 2020. "Kava and Its Kavalactones Inhibit Norepinephrine-Induced Intracellular Calcium Influx in Lung Cancer Cells." *Planta Med* 86 (1): 26–31. <https://doi.org/10.1055/a-1035-5183>.

Bousman, C. A., G. Murray, and K. M. Savage. 2012. "Kava for the Treatment of Generalized Anxiety." https://www.academia.edu/download/45247573/Kava_for_the_Treatment_of_Generalized_An20160501-19740-1mzgl6u.pdf.

Brown, Amy C., Janet Onopa, Peter Holck, Pakieli Kaufusi, Derek Kabasawa, Winston J. Craig, Klaus Dragull, Arie M. Levine, and Jonathan D. Baker. 2007. "Traditional Kava Beverage Consumption and Liver Function Tests in a Predominantly Tongan Population in Hawaii." *Clinical Toxicology* 45 (5): 549–56. <https://doi.org/10.1080/15563650701365875>.

Butt, Julia. 2019. *Kava Usage in Aboriginal and Pacific Islander Communities in Australia*. National Drug Research Institute.

Cagnacci, Angelo, Serenella Arangino, Antonietta Renzi, Anna Lisa Zanni, Stefania Malmusi, and Annibale Volpe. 2003. "Kava-Kava Administration Reduces Anxiety in Perimenopausal Women." *Maturitas* 44 (2): 103–9. [https://doi.org/10.1016/s0378-5122\(02\)00317-1](https://doi.org/10.1016/s0378-5122(02)00317-1).

Cairney, Sheree, Alan R. Clough, Paul Maruff, Alex Collie, Bart J. Currie, and Jon Currie. 2003. "Saccade and Cognitive Function in Chronic Kava Users." *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology* 28 (2): 389–96. <https://doi.org/10.1038/sj.npp.1300052>.

Cairney, Sheree, Paul Maruff, and Alan R. Clough. 2002. "The Neurobehavioural Effects of Kava." *The Australian and New Zealand Journal of Psychiatry* 36 (5): 657–62. <https://doi.org/10.1046/j.1440-1614.2002.01027.x>.

Cairney, Sheree, Paul Maruff, Alan R. Clough, Alex Collie, Jon Currie, and Bart J. Currie. 2003. "Saccade and Cognitive Impairment Associated with Kava Intoxication." *Human Psychopharmacology* 18 (7): 525–33. <https://doi.org/10.1002/hup.532>.

Capasso, A., and L. Sorrentino. 2005. "Pharmacological Studies on the Sedative and Hypnotic Effect of Kava Kava and Passiflora Extracts Combination." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 12 (1-2): 39–45. <https://doi.org/10.1016/j.phymed.2004.03.006>.

Catchpole, O. J., N. B. Perry, B. M. T. da Silva, J. B. Grey, and B. M. Smallfield. 2002. "Supercritical Extraction of Herbs I: Saw Palmetto, St John's Wort, Kava Root, and Echinacea." *The Journal of*

Supercritical Fluids 22 (2): 129–38. [https://doi.org/10.1016/S0896-8446\(01\)00110-3](https://doi.org/10.1016/S0896-8446(01)00110-3).

Cawte, J. 1985. "Psychoactive Substances of the South Seas: Betel, Kava and Pituri." *The Australian and New Zealand Journal of Psychiatry* 19 (1): 83–87. <https://doi.org/10.3109/00048678509158818>.

Cawte, John. 1986. "Parameters of Kava Used as a Challenge to Alcohol." *The Australian and New Zealand Journal of Psychiatry* 20 (1): 70–76. <https://doi.org/10.3109/00048678609158867>.

Celentano, Antonio, Andrew Tran, Claire Testa, Krishen Thayanantha, William Tan-Orders, Stephanie Tan, Mitali Syamal, Michael J. McCullough, and Tami Yap. 2019. "The Protective Effects of Kava (Piper Methysticum) Constituents in Cancers: A Systematic Review." *Journal of Oral Pathology & Medicine: Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology* 48 (7): 510–29. <https://doi.org/10.1111/jop.12900>.

Celentano, Antonio, Callisthenis Yiannis, Rita Paolini, Pangzhen Zhang, Camile S. Farah, Nicola Cirillo, Tami Yap, and Michael McCullough. 2020. "Kava Constituents Exert Selective Anticancer Effects in Oral Squamous Cell Carcinoma Cells in Vitro." *Scientific Reports* 10 (1): 1–11. <https://doi.org/10.1038/s41598-020-73058-4>.

Chambers, Megan I., Amy M. Osborne, and Rabi A. Musah. 2019. "Rapid Detection and Validated Quantification of Psychoactive Compounds in Complex Plant Matrices by Direct Analysis in Real Time-High Resolution Mass Spectrometry - Application to 'Kava' Psychoactive Pepper Products." *Rapid Communications in Mass Spectrometry: RCM* 33 (24): 1915–25. <https://doi.org/10.1002/rcm.8532>.

Chanwai, L. Giles. 2000. "Kava Toxicity." *Emergency Medicine Australasia: EMA* 12 (2): 142–45. <https://doi.org/10.1046/j.1442-2026.2000.00107.x>.

Chaurasiya, Narayan D., Francisco León, Yuanqing Ding, Isabel Gómez-Betancur, Dora Benjumea, Larry A. Walker, Stephen J. Cutler, and Babu L. Tekwani. 2017. "Interactions of Desmethoxyyangonin, a Secondary Metabolite from *Renealmia Alpina*, with Human Monoamine Oxidase-A and Oxidase-B." *Evidence-Based Complementary and Alternative Medicine: eCAM* 2017 (August): 4018724. <https://doi.org/10.1155/2017/4018724>.

Chou, Tsui-Wei, Jia-Hua Feng, Chi-Chang Huang, Ya-Wen Cheng, Shih-Chang Chien, Sheng-Yang Wang, and Lie-Fen Shyur. 2013. "A Plant Kavalactone Desmethoxyyangonin Prevents Inflammation and Fulminant Hepatitis in Mice." *PloS One* 8 (10): e77626. <https://doi.org/10.1371/journal.pone.0077626>.

Chua, Han Chow, Emilie T. H. Christensen, Kirsten Hoestgaard-Jensen, Leonny Y. Hartiadi, Iqbal Ramzan, Anders A. Jensen, Nathan L. Absalom, and Mary Chebib. 2016. "Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism." *PloS One* 11 (6): e0157700. <https://doi.org/10.1371/journal.pone.0157700>.

Clayton, Natasha P., Katsuhiko Yoshizawa, Grace E. Kissling, Leo T. Burka, Po-Chuen Chan, and Abraham Nyska. 2007. "Immunohistochemical Analysis of Expressions of Hepatic Cytochrome P450 in F344 Rats Following Oral Treatment with Kava Extract." *Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft Fur Toxikologische Pathologie* 58: 223–36. <https://doi.org/10.1016/j.etp.2006.08.002>.

Clouatre, Dallas L. 2004. "Kava Kava: Examining New Reports of Toxicity." *Toxicology Letters* 150: 85–96. <https://doi.org/10.1016/j.toxlet.2003.07.005>.

Clough, A. R. 2004. "Kava." *Reference Book for the CARPA Standard Treatment Manual, 4th Edition*. Darwin: Central Australian Rural Practitioners Association.
http://iempowerment.org/usb/iempowerment/healthcare/Mental_health_and_drug_problems/Kava.pdf.

Clough, A. R., S. P. Jacups, Z. Wang, C. B. Burns, R. S. Bailie, S. J. Cairney, A. Collie, T. Guyula, S. P. McDonald, and B. J. Currie. 2003. "Health Effects of Kava Use in an Eastern Arnhem Land Aboriginal Community." *Internal Medicine Journal* 33 (8): 336–40. <https://doi.org/10.1046/j.1444-0903.2003.00405.x>.

Clough, A. R., K. Rowley, and K. O'Dea. 2004. "Kava Use, Dyslipidaemia and Biomarkers of Dietary Quality in Aboriginal People in Arnhem Land in the Northern Territory (NT), Australia." *European Journal of Clinical Nutrition* 58 (7): 1090–93. <https://doi.org/10.1038/sj.ejcn.1601921>.

Clough, A. R., Z. Wang, R. S. Bailie, C. B. Burns, and B. J. Currie. 2004. "Case-Control Study of the Association between Kava Use and Ischaemic Heart Disease in Aboriginal Communities in Eastern Arnhem Land (Northern Territory) Australia." *Journal of Epidemiology and Community Health* 58 (2): 140–41. <https://doi.org/10.1136/jech.58.2.140>.

Clough, Alan. 2003. "Enough! Or Too Much. What Is 'Excessive' Kava Use in Arnhem Land?" *Drug and Alcohol Review* 22 (1): 43–51. <https://doi.org/10.1080/0959523021000059820>.

Clough, Alan R., Ross Bailie, Chris B. Burns, Terrence Guyula, Roslyn Wunungmurra, and Sylvia Rrepula Wanybarrnga. 2002. "Methods: Validity and Utility of Community Health Workers' Estimation of Kava Use." *Australian and New Zealand Journal of Public Health* 26 (1): 52–57.
<https://doi.org/10.1111/j.1467-842x.2002.tb00271.x>.

Clough, Alan R., Sheree Cairney, Paul Maruff, Chris B. Burns, and Bart J. Currie. 2001. "Possible Toxicity and Withdrawal Seizures in Aboriginal Kava Drinkers in Arnhem Land, (Australia)." *South Pacific Journal of Psychology* 13: 26–33. <https://doi.org/10.1017/S025754340000033X>.

Clough, Alan R., Bart J. Currie, Maymuna W. Yunupingu, and Katherine M. Conigrave. 2006. "Action Is Required to Reduce Kava Supply in Arnhem Land... Again!" *The Medical Journal of Australia* 184 (2): 91–92. <https://doi.org/10.5694/j.1326-5377.2006.tb00130.x>.

Clough, Alan R., and Peter J. Jones. 2004. "Policy Approaches to Support Local Community Control over the Supply and Distribution of Kava in the Northern Territory (Australia)." *Drug and Alcohol Review* 23 (1): 117–26. <https://doi.org/10.1080/09595230410001645619>.

Collocott, E. E. V. 1927. "KAVA CEREMONIAL IN TONGA." *The Journal of the Polynesian Society*. *Polynesian Society* 36 (1(141)): 21–47. <http://www.jstor.org/stable/20702121>.

Connell, John. 2007. "Towards Free Trade in the Pacific? The Genesis of the 'Kava-Biscuit War' between Fiji and Vanuatu." *Geographical Research* 45 (1): 1–12. <https://doi.org/10.1111/j.1745-5871.2007.00425.x>.

Connor, K. M., J. R. Davidson, and L. E. Churchill. 2001. "Adverse-Effect Profile of Kava." *CNS Spectrums* 6 (10): 848, 850–53. <https://doi.org/10.1017/s109285290000167x>.

Connor, K. M., and J. R. T. Davidson. 2002. "A Placebo-Controlled Study of Kava Kava in Generalized Anxiety Disorder." *International Clinical Psychopharmacology* 17 (4): 185–88. <https://doi.org/10.1097/00004850-200207000-00005>.

Connor, Kathryn M., Victoria Payne, and Jonathan R. T. Davidson. 2006. "Kava in Generalized Anxiety Disorder: Three Placebo-Controlled Trials." *International Clinical Psychopharmacology* 21 (5): 249–53. <https://doi.org/10.1097/00004850-200609000-00001>.

Costa, Willian Richardes, Lucas Rossi Sartori, and José C. Tavares Carvalho. 2010. "Study of In Vitro and In Vivo Extraction of Kavalactones of Pharmaceutical Form Containing Ground Plant Drug (Piper Methysticum G. Forster)." *Latin American Journal of Pharmacy* 29 (2): 289–92. https://www.academia.edu/download/49124391/Kavalactones_LAJP.pdf.

Côté, Cynthia S., Christine Kor, Jon Cohen, and Karine Auclair. 2004. "Composition and Biological Activity of Traditional and Commercial Kava Extracts." *Biochemical and Biophysical Research Communications* 322 (1): 147–52. <https://doi.org/10.1016/j.bbrc.2004.07.093>.

Coulter, David, Tamayo Carmen Sotheeswaran Subramaniam, Catherine Ulbricht, and World Health Organization. 2007. "Assessment of the Risk of Hepatotoxicity with Kava Products.pdf." World Health Organization.

Cox, Paul Alan, and Lisa O'Rourke. 1987. "Kava (Piper Methysticum, Piperaceae)." *Economic Botany* 41 (3): 452–54. <http://www.jstor.org/stable/4254999>.

D. Schmitz ,CL Zhang ,SS Chatterjee &U. Heinemann. 1995. "Effects of Methysticin on Three Different Models of Seizure like Events Studied in Rat Hippocampal and Entorhinal Cortex Slices." *Naunyn-Schmiedeberg's Archives of Pharmacology* 351: 348–55. <https://doi.org/10.1007/BF00169074>.

Dai, Jun-Qi, Yi-Gang Huang, and Ai-Na He. 2015. "Dihydromethysticin Kavalactone Induces Apoptosis in Osteosarcoma Cells through Modulation of PI3K/Akt Pathway, Disruption of Mitochondrial Membrane Potential and Inducing Cell Cycle Arrest." *International Journal of Clinical and Experimental Pathology* 8 (5): 4356–66. <https://www.ncbi.nlm.nih.gov/pubmed/26191127>.

Danan, Gaby, and Rolf Teschke. 2015. "RUCAM in Drug and Herb Induced Liver Injury: The Update." *International Journal of Molecular Sciences* 17 (1). <https://doi.org/10.3390/ijms17010014>.

Davies, L. P., C. A. Drew, P. Duffield, G. A. Johnston, and D. D. Jamieson. 1992. "Kava Pyrones and Resin: Studies on GABAA, GABAB and Benzodiazepine Binding Sites in Rodent Brain." *Pharmacology & Toxicology* 71 (2): 120–26. <https://doi.org/10.1111/j.1600-0773.1992.tb00530.x>.

De Leo, V., A. la Marca, G. Morgante, D. Lanzetta, P. Florio, and F. Petraglia. 2001. "Evaluation of Combining Kava Extract with Hormone Replacement Therapy in the Treatment of Postmenopausal Anxiety." *Maturitas* 39 (2): 185–88. [https://doi.org/10.1016/s0378-5122\(01\)00197-9](https://doi.org/10.1016/s0378-5122(01)00197-9).

Deihl, Joseph R. 1932. "Kava and Kava-Drinking." *Primitive Man* 5 (4): 61–68. <https://doi.org/10.2307/3316234>.

Denery, Judith R., Klaus Dragull, C. S. Tang, and Qing X. Li. 2004. "Pressurized Fluid Extraction of Carotenoids from *Haematococcus Pluvialis* and *Dunaliella Salina* and Kavalactones from *Piper Methysticum*." *Analytica Chimica Acta* 501 (2): 175–81. <https://doi.org/10.1016/j.aca.2003.09.026>.

Denham, Alison, Michael McIntyre, and Julie Whitehouse. 2002. "Kava—the Unfolding Story: Report on a Work-in-Progress." *The Journal of Alternative and Complementary Medicine* 8 (3): 237–63. <https://doi.org/10.1089/10755530260127943>.

Dentali, Steven J., Cristina Amarillas, Tyler Blythe, Paula N. Brown, Anton Bzhelyansky, Christine Fields, Holly E. Johnson, et al. 2018. "Standard Method Performance Requirements (SMPRs®) 2018.005: Determination of Kavalactones And/or Flavokavains from Kava (*Piper Methysticum*)." *Journal of AOAC International* 101 (4): 1256–60. <https://doi.org/10.5740/jaoacint.smpr2018.005>.

Department of Industry, Tourism and Trade. 2020. "KAVA MANAGEMENT ACT 1998." <https://legislation.nt.gov.au/Legislation/KAVA-MANAGEMENT-ACT-1998>.

Dharmaratne, H. Ranjith W., N. P. Dhammika Nanayakkara, and Ikhlās A. Khan. 2002. "Kavalactones from *Piper Methysticum*, and Their ¹³C NMR Spectroscopic Analyses." *Phytochemistry* 59 (4): 429–33. [https://doi.org/10.1016/s0031-9422\(01\)00443-5](https://doi.org/10.1016/s0031-9422(01)00443-5).

Diana Webster. 1999. "Cannibals and Kava." *The Hudson Review* 52 (2): 182–89. <https://doi.org/10.2307/3853398>.

Dietlein, G., and D. Schröder-Bernhardi. 2003. "Doctors' Prescription Behaviour Regarding Dosage Recommendations for Preparations of Kava Extracts." *Pharmacoepidemiology and Drug Safety* 12 (5): 417–21. <https://doi.org/10.1002/pds.839>.

Dinh, L. D., U. Simmen, K. B. Bueter, B. Bueter, K. Lundstrom, and W. Schaffner. 2001. "Interaction of Various Piper Methysticum Cultivars with CNS Receptors in Vitro." *Planta Medica* 67 (4): 306–11. <https://doi.org/10.1055/s-2001-14334>.

DiSilvestro, Robert A., Wenyi Zhang, and David J. DiSilvestro. 2007. "Kava Feeding in Rats Does Not Cause Liver Injury nor Enhance Galactosamine-Induced Hepatitis." *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association* 45 (7): 1293–1300. <https://doi.org/10.1016/j.fct.2007.01.015>.

Donadio, V., P. Bonsi, I. Zele, L. Monari, R. Liguori, R. Vetrugno, F. Albani, and P. Montagna. 2000. "Myoglobinuria after Ingestion of Extracts of Guarana, Ginkgo Biloba and Kava." *Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology* 21 (2): 124. <https://doi.org/10.1007/s100720070109>.

Dong, J., P. Kandukuru, A. S. Huang, and Y. Li. 2011. "PCR-DGGE Analysis of Bacterial Community Dynamics in Kava Beverages during Refrigeration." *Letters in Applied Microbiology* 53 (1): 30–34. <https://doi.org/10.1111/j.1472-765X.2011.03065.x>.

Dragull, Klaus, Wesley Y. Yoshida, and Chung-Shih Tang. 2003. "Piperidine Alkaloids from Piper Methysticum." *Phytochemistry* 63 (2): 193–98. [https://doi.org/10.1016/s0031-9422\(03\)00111-0](https://doi.org/10.1016/s0031-9422(03)00111-0).

Duffield, A. M., D. D. Jamieson, R. O. Lidgard, P. H. Duffield, and D. J. Bourne. 1989. "Identification of Some Human Urinary Metabolites of the Intoxicating Beverage Kava." *Journal of Chromatography* 475 (July): 273–81. [https://doi.org/10.1016/s0021-9673\(01\)89682-5](https://doi.org/10.1016/s0021-9673(01)89682-5).

Duffield, A. M., and R. O. Lidgard. 1986. "Analysis of Kava Resin by Gas Chromatography and Electron Impact and Methane Negative Ion Chemical Ionization Mass Spectrometry. New Trace Constituents of Kava Resin." *Biological Mass Spectrometry* 13 (11): 621–26. <https://doi.org/10.1002/bms.1200131107>.

Duffield, A. M., R. O. Lidgard, and G. K-C Low. 1986. "Analysis of the Constituents of Piper Methysticum by Gas Chromatography Methane Chemical Ionization Mass Spectrometry. New Constituents of Kava Resin." *Biological Mass Spectrometry* 13 (6): 305–13. <https://doi.org/10.1002/bms.1200130608>.

Duffield, P. H., and D. Jamieson. 1991. "Development of Tolerance to Kava in Mice." *Clinical and Experimental Pharmacology & Physiology* 18 (8): 571–78. <https://doi.org/10.1111/j.1440-1681.1991.tb01493.x>.

Duve, R. N. 1981. "Gas-Liquid Chromatographic Determination of Major Constituents of Piper Methysticum." *The Analyst* 106 (1259): 160–65. <https://doi.org/10.1039/AN9810600160>.

Einbond, L. S., A. Negrin, D. M. Kulakowski, H-A Wu, V. Antonetti, F. Jalees, W. Law, et al. 2017. "Traditional Preparations of Kava (Piper Methysticum) Inhibit the Growth of Human Colon Cancer Cells in Vitro." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 24 (January): 1–13. <https://doi.org/10.1016/j.phymed.2016.11.002>.

Ernst, E. 2002. "Safety Concerns about Kava." *The Lancet* 359 (9320): 1865. [https://doi.org/10.1016/S0140-6736\(02\)08696-8](https://doi.org/10.1016/S0140-6736(02)08696-8).

———. 2007. "A Re-Evaluation of Kava (Piper Methysticum)." *British Journal of Clinical Pharmacology* 64 (4): 415–17. <https://doi.org/10.1111/j.1365-2125.2007.02932.x>.

Ernst, Edzard. 2002a. "The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava." *Annals of Internal Medicine* 136 (1): 42–53. <https://doi.org/10.7326/0003-4819-136-1-200201010-00010>.

———. 2002b. "Second Thoughts about Kava." *The American Journal of Medicine* 113 (4): 347–48. [https://doi.org/10.1016/S0002-9343\(02\)01204-4](https://doi.org/10.1016/S0002-9343(02)01204-4).

Fehoko, E. 2013. "From Kava to Coffee: Tongan Young People in Auckland." *Mana Ngākau: Community Compassion Māori and*. https://www.academia.edu/download/33781543/From_Kava_to_Coffee_Tongan_Young_People_in_Auckland.pdf.

Fehoko, E., I. Hafoka, and A. Tecun. 2021. "Holding Tightly onto Land and People During a Pandemic: Kava Pedagogies and Tertiary Learning Relationships in Vahaope." *Researchgate.net*. https://www.researchgate.net/profile/Arcia-Tecun-Daniel-Hernandez/publication/349211981_Holding_Tightly_onto_Land_and_People_During_a_Pandemic_Kava_Pedagogies_and_Tertiary_Learning_Relationships_in_Vahaope/links/6025078ca6fdcc37a81a9fca/Holding-Tightly-onto-Land-and-People-During-a-Pandemic-Kava-Pedagogies-and-Tertiary-Learning-Relationships-in-Vahaope.pdf.

Feldman, Harry. 1980. "INFORMAL KAVA DRINKING IN TONGA." *The Journal of the Polynesian Society*. *Polynesian Society* 89 (1): 101–3. <http://www.jstor.org/stable/20705463>.

Feltenstein, Matt W., L. Corinne Lambdin, M. Ganzera, H. Ranjith, W. Dharmaratne, N. P. Dhammika Nanayakkara, Ikhlas A. Khan, and Kenneth J. Sufka. 2003. "Anxiolytic Properties of Piper Methysticum Extract Samples and Fractions in the Chick Social-Separation-Stress Procedure." *Phytotherapy Research: PTR* 17 (3): 210–16. <https://doi.org/10.1002/ptr.1107>.

Ferreira, Juliana Veloso, Isabella Campolina Pierotte, Gerson Antônio Pianetti, and Isabela Costa César. 2020. "Simultaneous Quantitation of Kavalactones in Kava Dry Extracts: Comparison of Multi-Standards and Single Standard Validation Approaches." *Phytochemical Analysis: PCA*, December. <https://doi.org/10.1002/pca.3019>.

Finau, S. A., J. M. Stanhope, and I. A. Prior. 1982. "Kava, Alcohol and Tobacco Consumption among Tongans with Urbanization." *Social Science & Medicine* 16 (1): 35–41. [https://doi.org/10.1016/0277-9536\(82\)90421-x](https://doi.org/10.1016/0277-9536(82)90421-x).

Flynn, Nicole. 2016. "Comparison of the Anxiolytic Effects of Diazepam and Kava on Behaviour in Rats." Master of Arts, University of Canterbury. <http://ir.canterbury.ac.nz/handle/10092/12806>.

Foo, H., and J. Lemon. 1997. "Acute Effects of Kava, Alone or in Combination with Alcohol, on Subjective Measures of Impairment and Intoxication and on Cognitive Performance." *Drug and Alcohol Review* 16 (2): 147–55. <https://doi.org/10.1080/09595239700186441>.

Food and Agriculture Organization of the United Nations, and WHO. 2016. "Kava: A Review of the Safety of Traditional and Recreational Beverage Consumption."

Food Standards Australia New Zealand. 2004. "KAVA A Human Health Risk Assessment." 30.

Fragoulis, Athanassios, Stephanie Siegl, Markus Fendt, Sandra Jansen, Ulf Soppa, Lars-Ove Brandenburg, Thomas Pufe, Joachim Weis, and Christoph Jan Wruck. 2017. "Oral Administration of Methysticin Improves Cognitive Deficits in a Mouse Model of Alzheimer's Disease." *Redox Biology* 12 (August): 843–53. <https://doi.org/10.1016/j.redox.2017.04.024>.

Fu, Dong, and Iqbal Ramzan. 2015. "Use of Kava as a Phytotherapeutic Agent and Kava-Related Hepatotoxicity." *Phytotherapies*, 312–29. <https://doi.org/10.1002/9781119006039.ch13>.

Fu, Peter P., Qingsu Xia, Lei Guo, Hongtao Yu, and Po-Chuen Chan. 2008. "Toxicity of Kava Kava." *Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews* 26 (1): 89–112. <https://doi.org/10.1080/10590500801907407>.

Fu, Shuang, J. Perl, S. Jennings, and M. Hepburn. 2019. "Kava Influence on Driving Skills: A Case Study." In *Conference Proceedings: 22nd International Council on Alcohol, Drugs and Traffic Safety Conference*, 145–48. [vpp-seidl.de. https://vpp-seidl.de/ueberuns/t2019/content_117567/ICADTS_T2019_ConferenceProceedings.pdf#page=146](https://vpp-seidl.de/ueberuns/t2019/content_117567/ICADTS_T2019_ConferenceProceedings.pdf#page=146).

Fu, Shuang, Anthony Rowe, and Iqbal Ramzan. 2012. "Kavalactone Metabolism in the Isolated Perfused Rat Liver." *Phytotherapy Research: PTR* 26 (12): 1813–16. <https://doi.org/10.1002/ptr.4656>.

Furguele, A. R., W. J. Kinnard, M. D. Aceto, and J. P. Buckley. 1965. "CENTRAL ACTIVITY OF AQUEOUS

EXTRACTS OF PIPER METHYSTICUM (KAVA).” *Journal of Pharmaceutical Sciences* 54 (February): 247–52. <https://doi.org/10.1002/jps.2600540218>.

Garner, L. F., and J. D. Klinger. 1985. “Some Visual Effects Caused by the Beverage Kava.” *Ethnopharmacol.* 13 (3): 307–11. [https://doi.org/10.1016/0378-8741\(85\)90076-5](https://doi.org/10.1016/0378-8741(85)90076-5).

Gastpar, M., and H. D. Klimm. 2003. “Treatment of Anxiety, Tension and Restlessness States with Kava Special Extract WS 1490 in General Practice: A Randomized Placebo-Controlled Double-Blind Multicenter Trial.” *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 10 (8): 631–39. <https://doi.org/10.1078/0944-7113-00369>.

Gatty, Ronald. 1956. “Kava—polynesian Beverage Shrub.” *Economic Botany* 10 (3): 241–49. <https://doi.org/10.1007/BF02898999>.

Geier, F. P., and T. Konstantinowicz. 2004. “Kava Treatment in Patients with Anxiety.” *Phytotherapy Research: PTR* 18 (4): 297–300. <https://doi.org/10.1002/ptr.1422>.

Gendle, M. H., A. K. Stroman, and D. P. Mullin. 2011. “Effect of an Acute Dose of Crude Kava Root Extract on Problem Solving in Healthy Young Adults.” *Australian Journal of Medical Herbalism* 23 (4): 160–63. <https://search.informit.org/doi/abs/10.3316/informit.858304482995950>.

Gerren, Andrew. 2017. “Effects of Varietal Diversity on Knowledge of Kava (Piper Methysticum) in the Pacific.” *University of Hawaii at Manoa*, May. <http://128.171.57.22/handle/10125/56539>.

Girman, Andrea, Roberta Lee, and Benjamin Kligler. 2003. “An Integrative Medicine Approach to Premenstrual Syndrome.” *American Journal of Obstetrics and Gynecology* 188 (5 Suppl): S56–65. <https://doi.org/10.1067/mob.2003.403>.

Gleitz, J., A. Beile, and T. Peters. 1996. “(+/-)-Kavain Inhibits the Veratridine- and KCl-Induced Increase in Intracellular Ca²⁺ and Glutamate-Release of Rat Cerebrocortical Synaptosomes.” *Neuropharmacology* 35 (2): 179–86. [https://doi.org/10.1016/0028-3908\(95\)00163-8](https://doi.org/10.1016/0028-3908(95)00163-8).

Gleitz, J., A. Beile, P. Wilkens, A. Ameri, and Peters T. 1997. “Gleitz1’ et Al. - 1997 - Antithrombotic Action of the Kava Pyrone (-)-Kavain Prepared from Piper Methysticum on Human Platelets.” *Planta Medica* 63 (1): 27–30. <https://doi.org/10.1055/s-2006-957597>.

Gleitz, J., J. Friese, A. Beile, A. Ameri, and T. Peters. 1996. “Anticonvulsive Action of (+/-)-Kavain Estimated from Its Properties on Stimulated Synaptosomes and Na⁺ Channel Receptor Sites.” *European Journal of Pharmacology* 315 (1): 89–97. [https://doi.org/10.1016/s0014-2999\(96\)00550-x](https://doi.org/10.1016/s0014-2999(96)00550-x).

Gleitz, J., N. Gottner, A. Ameri, and T. Peters. 1996. “Kavain Inhibits Non-Stereospecifically Veratridine-Activated Na⁺ Channels.” *Planta Medica* 62 (6): 580–81. <https://doi.org/10.1055/s-2006-957981>.

Gleitz, J., C. Tosch, A. Beile, and T. Peters. 1996. "The Protective Action of Tetrodotoxin and (+/-)-Kavain on Anaerobic Glycolysis, ATP Content and Intracellular Na⁺ and Ca²⁺ of Anoxic Brain Vesicles." *Neuropharmacology* 35 (12): 1743–52. [https://doi.org/10.1016/s0028-3908\(96\)00106-2](https://doi.org/10.1016/s0028-3908(96)00106-2).

Gow, Paul J., Nathan J. Connelly, Richard L. Hill, Peter Crowley, and Peter W. Angus. 2003. "Fatal Fulminant Hepatic Failure Induced by a Natural Therapy Containing Kava." *The Medical Journal of Australia* 178 (9): 442–43. <https://doi.org/10.5694/j.1326-5377.2003.tb05286.x>.

Grace, Robert. 2005. "Kava-Induced Urticaria." *Journal of the American Academy of Dermatology* 53 (5): 906. <https://doi.org/10.1016/j.jaad.2005.04.068>.

Grace, Robert F. 2003. "Kava Drinking in Vanuatu--a Hospital Based Survey." *Pacific Health Dialog* 10 (2): 41–44. <https://www.ncbi.nlm.nih.gov/pubmed/18181414>.

Gregory, R. J., J. E. Gregory, and J. G. Peck. 1981. "Kava and Prohibition in Tanna, Vanuatu." *British Journal of Addiction* 76 (3): 299–313. <https://doi.org/10.1111/j.1360-0443.1981.tb00236.x>.

Groth-Marnat, G., S. Leslie, and M. Renneker. 1996. "Tobacco Control in a Traditional Fijian Village: Indigenous Methods of Smoking Cessation and Relapse Prevention." *Social Science & Medicine* 43 (4): 473–77. [https://doi.org/10.1016/0277-9536\(95\)00425-4](https://doi.org/10.1016/0277-9536(95)00425-4).

Gruenwald, Joerg, and Juergen Skrabal. 2003. "Kava Ban Highly Questionable: A Brief Summary of the Main Scientific Findings Presented in the 'in Depth Investigation on EU Member States Market Restrictions on Kava Products.'" *Seminars in Integrative Medicine* 1 (4): 199–210. <https://doi.org/10.1016/j.sigm.2004.01.001>.

Grunze, Heinz, Jens Langosch, Karin Schirmacher, Dieter Bingmann, Jörg von Wegerer, and Jörg Walden. 2001. "Kava Pyrones Exert Effects on Neuronal Transmission and Transmembraneous Cation Currents Similar to Established Mood Stabilizers - a Review." *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 25 (8): 1555–70. [https://doi.org/10.1016/S0278-5846\(01\)00208-1](https://doi.org/10.1016/S0278-5846(01)00208-1).

Guo, Lei, Qiang Shi, Stacey Dial, Qingsu Xia, Nan Mei, Quan-Zhen Li, Po-Chuen Chan, and Peter Fu. 2010. "Gene Expression Profiling in Male B6C3F1 Mouse Livers Exposed to Kava Identifies--Changes in Drug Metabolizing Genes and Potential Mechanisms Linked to Kava Toxicity." *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association* 48 (2): 686–96. <https://doi.org/10.1016/j.fct.2009.11.050>.

Gurgel Andrade Pedrosa, Elaine Cristina, Ana Paula Carvalho Bezerra, Ianara Mendonça da Costa, Francisco Irochima Pinheiro, and Fausto Pierdoná Guzen. 2020. "Neuroprotective Profile of Piper Methysticum (Kava Kava) and Its Effects on the Central Nervous System: A Systematic Review." *Journal of Pharmacological Chemistry and Biological Sciences* 2 (1): 55–84.

<https://doi.org/10.36619/jpcbs.2020.2.56.80>.

Gurley, Bill J., Ashley Swain, Martha A. Hubbard, D. Keith Williams, Gary Barone, Faith Hartsfield, Yudong Tong, Danielle J. Carrier, Shreekar Cheboyina, and Sunil K. Battu. 2008. "Clinical Assessment of CYP2D6-Mediated Herb-Drug Interactions in Humans: Effects of Milk Thistle, Black Cohosh, Goldenseal, Kava Kava, St. John's Wort, and Echinacea." *Molecular Nutrition & Food Research* 52 (7): 755–63. <https://doi.org/10.1002/mnfr.200600300>.

Guro-Razuman, S., P. Anand, Q. Hu, and R. Mir. 1999. "Dermatomyositis-like Illness Following Kava-Kava Ingestion." *Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases* 5 (6): 342–45. <https://doi.org/10.1097/00124743-199912000-00008>.

H.B. NO. 2494 - 'Awa; Official State Beverage of Hawaii. 2018. https://www.capitol.hawaii.gov/session2018/bills/HB2494_.HTM.

Haddon, A. C. 1916. "87. Kava-Drinking in New Guinea." *Man* 16: 145–52. <https://doi.org/10.2307/2787543>.

Hannam, Sarah, Michael Murray, Lucia Romani, Meciusela Tuicakau, and Margot J Whitfeld. 2014. "Kava Dermopathy in Fiji: An Acquired Ichthyosis?" *International Journal of Dermatology* 53 (12): 1490–94. <https://doi.org/10.1111/ijd.12546>.

HANSELL, R. 1968. "Characterization and Physiological Activity of Some Kava Constituents." *Pacific Science* 22: 293–313.

Hegazy, Nada Hany, Hans-Georg Breitingner, and Ulrike Breitingner. 2019. "Kavalactones from Kava (Piper Methysticum) Root Extract as Modulators of Recombinant Human Glycine Receptors." *Biological Chemistry* 400 (9): 1205–15. <https://doi.org/10.1515/hsz-2019-0112>.

Heinze, H. J. 1994. "Pharmacopsychological Effects of Oxazepam and Kava-Extract in a Visual Search Paradigm Assessed with Event-Related Potentials." *Pharmacopsychiat.* 27: 224–30.

Herberg, K. W. 1993. "[Effect of Kava-Special Extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters]." *Blutalkohol* 30 (2): 96–105. <https://www.ncbi.nlm.nih.gov/pubmed/8481222>.

Hj, Kretzschmar R. Meyer Hj. 1970. "Strychnine Antagonistic Potency of Pyrone Compounds of the Kava Root (Piper Methysticum Forst.)." *Experientia* 15 (26): 283–84. <https://doi.org/10.1007/BF01900097>.

Hocart, C. H., B. Fankhauser, and D. W. Buckle. 1993. "Chemical Archaeology of Kava, a Potent Brew." *Rapid Communications in Mass Spectrometry: RCM* 7 (3): 219–24. <https://doi.org/10.1002/rcm.1290070311>.

Holm, E., U. Staedt, J. Heep, C. Kortsik, F. Behne, A. Kaske, and I. Mennicke. 1991. "The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness-rhythm in animals." *Arzneimittel-Forschung* 41 (7): 673–83. <https://www.ncbi.nlm.nih.gov/pubmed/1772452>.

Hong, Nguyen Huu, Tran Dang Xuan, Tsuzuki Eiji, Mitsuhiro Matsuo, and Ogushi Yuichi. 2002. "Evaluation of the Allelopathic Potential of Kava (Piper Methysticum L.) for Weed Control in Rice." *Weed Biology and Management* 2 (3): 143–47. <https://doi.org/10.1046/j.1445-6664.2002.00062.x>.

Hoover, Jason M., Alan D. Kaye, Ikhlass N. Ibrahim, Aaron M. Fields, and Todd A. Richards. 2006. "Analysis of Responses to Kava Kava in the Feline Pulmonary Vascular Bed." *Journal of Medicinal Food* 9 (1): 62–71. <https://doi.org/10.1089/jmf.2006.9.62>.

Hough, Walter. 1905. "Kava Drinking as Practised by the Papuans and Polynesians." *Smithsonian Miscellaneous Collections*.
https://repository.si.edu/bitstream/handle/10088/23253/SMC_47_Hough_1905_5_85-92.pdf.

Hussein, Anan. 2015. "A Closer Look at the Risks vs. Benefits of Kava (Piper Methysticum)." *Journal of Student Research* 4 (2): 69–72. <https://doi.org/10.47611/jsr.v4i2.245>.

Huynh, J. C., M. M. Asgari, and M. M. Moore. 2014. "Sebotropic Eruption Associated with Use of Oral Kava Kava Supplement." *Clinical and Experimental Dermatology* 39 (7): 816–18.
<https://doi.org/10.1111/ced.12439>.

IARC. 2013. "Kava." In *Some Drugs and Herbal Products*, 117–40.

"Increasing Consumer Access to Kava." n.d. Accessed April 19, 2021.
<https://www.odc.gov.au/publications/increasing-consumer-access-kava>.

Jager, L. S. de, G. A. Perfetti, and G. W. Diachenko. 2004. "LC-UV and LC-MS Analysis of Food and Drink Products Containing Kava." *Food Additives and Contaminants* 21 (10): 921–34.
<https://doi.org/10.1080/02652030400010454>.

Jaiswal, Yogini S., Aaron M. Yerke, M. Caleb Bagley, Mans Ekelof, Daniel Weber, Daniel Haddad, Anthony Fodor, David C. Muddiman, and Leonard L. Williams. 2020. "3D Imaging and Metabolomic Profiling Reveal Higher Neuroactive Kavalactone Contents in Lateral Roots and Crown Root Peels of Piper Methysticum (kava)." *GigaScience* 9 (9). <https://doi.org/10.5524/100784>.

Jaiswal, Yogini, Mohd Farooq Shaikh, Ilya Wang, Yanning Yong, Vanessa Lin Lin Lee, and Leonard Williams. 2020. "Evaluation of Anti-Convulsive Properties of Aqueous Kava Extract on Zebrafish Using the PTZ-Induced Seizure Model." *Brain Sciences* 10 (8). <https://doi.org/10.3390/brainsci10080541>.

JAMES, Kerry. 1999. "Alcohol: A Threat to Tonga's Time Honored Values?" *Pacifichealthdialog.org.fj* 6 (2): 261–64.

<http://pacifichealthdialog.org.fj/Volume206/No220Health20of20Tongans20and20other20Pacifians/Reprint20Papers/Alcohol20a20threat20to20Tongas20time20honoured20values.pdf>.

Jamieson, D. D., and P. H. Duffield. 1990a. "Positive Interaction of Ethanol and Kava Resin in Mice." *Clinical and Experimental Pharmacology & Physiology* 17 (7): 509–14. <https://doi.org/10.1111/j.1440-1681.1990.tb01350.x>.

———. 1990b. "The Antinociceptive Actions of Kava Components in Mice." *Clinical and Experimental Pharmacology & Physiology* 17 (7): 495–507. <https://doi.org/10.1111/j.1440-1681.1990.tb01349.x>.

Jamieson, D. D., P. H. Duffield, D. Cheng, and A. M. Duffield. 1989. "Comparison of the Central Nervous System Activity of the Aqueous and Lipid Extract of Kava (Piper Methysticum)." *Archives Internationales de Pharmacodynamie et de Therapie* 301 (September): 66–80. <https://www.ncbi.nlm.nih.gov/pubmed/2624517>.

Jandial, Danielle D., Lauren S. Krill, Lixia Chen, Chunli Wu, Yu Ke, Jun Xie, Bang H. Hoang, and Xiaolin Zi. 2017. "Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin." *Molecules* 22 (3). <https://doi.org/10.3390/molecules22030462>.

Jappe, U., I. Franke, D. Reinhold, and H. P. Gollnick. 1998. "Sebotropic Drug Reaction Resulting from Kava-Kava Extract Therapy: A New Entity?" *Journal of the American Academy of Dermatology* 38 (1): 104–6. [https://doi.org/10.1016/s0190-9622\(98\)70547-x](https://doi.org/10.1016/s0190-9622(98)70547-x).

Jayararnan, T. K. 2004. "COPING WITH VULNERABILITY BY BUILDING ECONOMIC RESILIENCE: THE CASE OF VANUATU." In *Economic Vulnerability and Resilience of Small States*, 135–48. University of Malta. Islands and Small States Institute & The Commonwealth Secretariat.

Jhoo, J-W, J. P. Freeman, C. Y. W. Ang, and J. J. Mihalov. 2006. "Assessment of Kavalactones in Kava Beverage Products and Aqueous Infusions." *Journal of Food Science* 71 (6): C345–51. <https://doi.org/10.1111/j.1750-3841.2006.00102.x>.

Jhoo, Jin-Woo, James P. Freeman, Thomas M. Heinze, Joanna D. Moody, Laura K. Schnackenberg, Richard D. Beger, Klaus Dragull, Chung-Shih Tang, and Catharina Y. W. Ang. 2006. "In Vitro Cytotoxicity of Nonpolar Constituents from Different Parts of Kava Plant (Piper Methysticum)." *Journal of Agricultural and Food Chemistry* 54 (8): 3157–62. <https://doi.org/10.1021/jf051853j>.

Ji, Fei. 2014. "Pass the Kava: Implications for Patent Protections over Traditional Knowledge in Samoa's New Intellectual Property Act of 2011." *Hous. J. Int'l L.* 36: 789. https://heinonline.org/hol-cgi-bin/get_pdf.cgi?handle=hein.journals/hujil36§ion=26.

Johana, A. Mendes, Y. Ekowati Nurhening, S. Susanti Diana, Sembiring Jefri, Prasetia Andri, and Widijastuti Rosmala. 2018. "The Potential Leaves Extract of Piper Methysticum (piperaceae) as Botanical Insecticide against Crocidolomia Pavonana (f.) Larvae Mortality (lepidoptera:crambidae)." *E3S Web of Conferences* 73: 06015. <https://doi.org/10.1051/e3sconf/20187306015>.

Johnson, Benjamin M., Sheng-Xiang Qiu, Shide Zhang, Fagen Zhang, Joanna E. Burdette, Linning Yu, Judy L. Bolton, and Richard B. van Breemen. 2003. "Identification of Novel Electrophilic Metabolites of Piper Methysticum Forst (Kava)." *Chemical Research in Toxicology* 16 (6): 733–40. <https://doi.org/10.1021/tx020113r>.

Johnson, Thomas E., David Hermanson, Lei Wang, Fekadu Kassie, Pramod Upadhyaya, Michael G. O'Sullivan, Stephen S. Hecht, Junxuan Lu, and Chengguo Xing. 2011. "Lung Tumorigenesis Suppressing Effects of a Commercial Kava Extract and Its Selected Compounds in A/J Mice." *The American Journal of Chinese Medicine* 39 (4): 727–42. <https://doi.org/10.1142/S0192415X11009202>.

Johnson, Thomas E., Fekadu Kassie, M. Gerard O'Sullivan, Mesfin Negia, Timothy E. Hanson, Pramod Upadhyaya, Peter P. Ruvolo, Stephen S. Hecht, and Chengguo Xing. 2008. "Chemopreventive Effect of Kava on 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone plus Benzo[a]pyrene-Induced Lung Tumorigenesis in A/J Mice." *Cancer Prevention Research* 1 (6): 430–38. <https://doi.org/10.1158/1940-6207.CAPR-08-0027>.

Jokhan, Anjeela D., and Patricia A. McLenachan. 2004. "Genetic Fingerprinting of Fijian Kava." *The South Pacific Journal of Natural and Applied Sciences* 22 (1): 43–45. <https://doi.org/10.1071/sp04008>.

Jussofie, A., A. Schmiz, and C. Hiemke. 1994. "Kavapyrone Enriched Extract from Piper Methysticum as Modulator of the GABA Binding Site in Different Regions of Rat Brain." *Psychopharmacology* 116 (4): 469–74. <https://doi.org/10.1007/BF02247480>.

Kandukuru, P., A. S. Huang, J. Dong, H. C. Bittenbender, and Y. Li. 2009. "Rapid Identification of Bacterial Isolates from Aqueous Kava (Piper Methysticum) Extracts by Polymerase Chain Reaction and DNA Sequencing." *Letters in Applied Microbiology* 49 (6): 764–68. <https://doi.org/10.1111/j.1472-765X.2009.02739.x>.

Kautu, Bwarenaba B., Juliana Phillips, Kellie Steele, M. Shawn Mengarelli, and Eric A. Nord. 2017. "A Behavioral Survey of the Effects of Kavalactones on Caenorhabditis Elegans Neuromuscular Transmission." *Journal of Experimental Neuroscience* 11 (June): 1179069517705384. <https://doi.org/10.1177/1179069517705384>.

"Kava." n.d. Accessed May 5, 2021. <https://www.betterhealth.vic.gov.au/health/healthyliving/kava>.

Keledjian, J., P. H. Duffield, D. D. Jamieson, R. O. Lidgard, and A. M. Duffield. 1988. "Uptake into Mouse

Brain of Four Compounds Present in the Psychoactive Beverage Kava.” *Journal of Pharmaceutical Sciences* 77 (12): 1003–6. <https://doi.org/10.1002/jps.2600771203>.

Keohohou, Saffery And Nicki. 1998. “NY NY1693 - The Tariff Classification of Kava.” United States International Trade Commision Rulings And Harmonized Tariff Schedule. 1998 NY Rulings. <http://www.faqs.org/rulings/rulings1998NYNY1693.html>.

Ketola, Raimo A., Jenni Viinamäki, Ilpo Rasanen, Anna Pelander, and Sirkka Goebeler. 2015. “Fatal Kavalactone Intoxication by Suicidal Intravenous Injection.” *Forensic Science International* 249 (April): e7–11. <https://doi.org/10.1016/j.forsciint.2015.01.032>.

Klaus Dragull Jim Henderson Mel C. Jackson Ed Johnston Jerry Konanui G. David Lin Kepā Maly Scot Nelson Jeri Ooka Tom Osborn Helen Rogers Chung-Shih Tang. 2006. *Hawaiian ‘Awa Views of an Ethnobotanical Treasure*. Edited by Ed Johnston and Helen Rogers. Association for Hawaiian ‘Awa.

Klohs, M. W., Keller, F., Williams, R. E., Toekes, M. I., Cronheim, G. E. 1959. “A Chemical and Pharmacological Investigation of Piper Methysticum Forst.” *Journal of Medicinal and Pharmaceutical Chemistry* 1 (1): 95–103. <https://doi.org/10.1021/jm50002a007>.

Kong, Yulong, Xiaoguang Gao, Changyuan Wang, Chenqing Ning, Kexin Liu, Zhihao Liu, Huijun Sun, Xiaodong Ma, Pengyuan Sun, and Qiang Meng. 2018. “Protective Effects of Yangonin from an Edible Botanical Kava against Lithocholic Acid-Induced Cholestasis and Hepatotoxicity.” *European Journal of Pharmacology* 824 (April): 64–71. <https://doi.org/10.1016/j.ejphar.2018.02.002>.

Krum, Bárbara Nunes, Catiuscia Molz de Freitas, Ana Paula Chiapinotto Ceretta, Caroline Pilecco Barbosa, Elizete de Moraes Reis, Rahisa Scussel, Emily da Silva Córneo, Ricardo Andrez Machado-de-Ávila, Aline Augusti Boligon, and Roselei Fachinetto. 2021. “Kava Decreases the Stereotyped Behavior Induced by Amphetamine in Mice.” *Journal of Ethnopharmacology* 265 (January): 113293. <https://doi.org/10.1016/j.jep.2020.113293>.

Kubátová, A., D. J. Miller, and S. B. Hawthorne. 2001. “Comparison of Subcritical Water and Organic Solvents for Extracting Kava Lactones from Kava Root.” *Journal of Chromatography. A* 923 (1-2): 187–94. [https://doi.org/10.1016/S0021-9673\(01\)00979-7](https://doi.org/10.1016/S0021-9673(01)00979-7).

Kuchta, Kenny, Marie Hladikova, Michael Thomsen, Adolf Nahrstedt, and Mathias Schmidt. 2021. “Kava (Piper Methysticum) Extract for the Treatment of Nervous Anxiety, Tension and Restlessness.” *Drug Research* 71 (2): 83–93. <https://doi.org/10.1055/a-1268-7135>.

Kuchta, Kenny, Pietro de Nicola, and Mathias Schmidt. 2018. “Randomized, Dose-Controlled Double-Blind Trial: Efficacy of an Ethanolic Kava (Piper Methysticum Rhizome) Extract for the Treatment of Anxiety in Elderly Patients: Kava Extract for Anxiety.” *Traditional & Kampo Medicine* 5 (1): 3–10. <https://doi.org/10.1002/tkm2.1079>.

Kuchta, Kenny, Mathias Schmidt, and Adolf Nahrstedt. 2015. "German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (*Piper Methysticum*) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics." *Planta Medica* 81 (18): 1647–53. <https://doi.org/10.1055/s-0035-1558295>.

Kumagai, Momochika, Keisuke Nishikawa, Takashi Mishima, Izumi Yoshida, Masahiro Ide, Akio Watanabe, Kazuhiro Fujita, and Yoshiki Morimoto. 2020. "Fluorinated Kavalactone Inhibited RANKL-Induced Osteoclast Differentiation of RAW264 Cells." *Biological & Pharmaceutical Bulletin* 43 (5): 898–903. <https://doi.org/10.1248/bpb.b20-00063>.

LaPorte, E., J. Sarris, C. Stough, and A. Scholey. 2011. "Neurocognitive Effects of Kava (*Piper Methysticum*): A Systematic Review." *Human Psychopharmacology* 26 (2): 102–11. <https://doi.org/10.1002/hup.1180>.

Lasme, Privat, Fabrice Davrieux, Didier Montet, and Vincent Lebot. 2008. "Quantification of Kavalactones and Determination of Kava (*Piper Methysticum*) Chemotypes Using near-Infrared Reflectance Spectroscopy for Quality Control in Vanuatu." *Journal of Agricultural and Food Chemistry* 56 (13): 4976–81. <https://doi.org/10.1021/jf800439g>.

Lebot, V. 1996. "Evidence for Conspecificity of *Piper Methysticum* Forst. F. and *Piper Wichmannii* C. DC." *Biochemical Systematics and Ecology*. [https://doi.org/10.1016/s0305-1978\(97\)81216-1](https://doi.org/10.1016/s0305-1978(97)81216-1).

———. 2018. "Recent Advances in the Quality Control of Kava, the Traditional Beverage of the Pacific Islands." *Acta Horticulturae*, no. 1205 (June): 483–92. <https://doi.org/10.17660/actahortic.2018.1205.59>.

Lebot, V., T. K. T. Do, and L. Legendre. 2014. "Detection of Flavokavins (A, B, C) in Cultivars of Kava (*Piper Methysticum*) Using High Performance Thin Layer Chromatography (HPTLC)." *Food Chemistry* 151 (May): 554–60. <https://doi.org/10.1016/j.foodchem.2013.11.120>.

Lebot, V., and J. Lèvesque. 1989. "THE ORIGIN AND DISTRIBUTION OF KAVA (*PIPER METHYSTICUM* FORST. F., *PIPERACEAE*): A PHYTOCHEMICAL APPROACH." *Allertonia* 5 (2): 223–81. <http://www.jstor.org/stable/23187398>.

Lebot, Vincent. 1995. "The Origin And Distribution Of Kava." *Canberra Anthropology* 18 (1-2): 20–33. <https://doi.org/10.1080/03149099509508407>.

Lebot, Vincent, z. Mallikarjuna K. Aradhya, and Richard M. Manshardt. 1991. "Geographic Survey of Genetic Variation in Kava (*Piper Methysticum* Forst. F. and *P. Wichmannii* C. DC.)." *Pacific Science* 45 (2): 169–85. <http://hdl.handle.net/10125/518>.

Lebot Vincent, Cabalion Pierre. 1988. *KAVAS OF VANUATU Cultivars of Piper Methysticum Forst.* South Pacific Commission Technical Paper.

Lebot, Vincent, Juliane Kaoh, and Laurent Legendre. 2020. "High-Throughput Analysis of Flavokawains in Kava (*Piper Methysticum* Forst. F.) Roots, Chips and Powders and Correlations with Their Acetonic Extracts Absorbance." *Food Analytical Methods* 13 (8): 1583–93. <https://doi.org/10.1007/s12161-020-01781-9>.

Lebot, Vincent, and Laurent Legendre. 2016. "Comparison of Kava (*Piper Methysticum* Forst.) Varieties by UV Absorbance of Acetonic Extracts and High-Performance Thin-Layer Chromatography." *Journal of Food Composition and Analysis: An Official Publication of the United Nations University, International Network of Food Data Systems* 48 (May): 25–33. <https://doi.org/10.1016/j.jfca.2016.01.009>.

Lebot, Vincent, and Joël Levesque. 1996. "Genetic Control of Kavalactone Chemotypes in *Piper Methysticum* Cultivars." *Phytochemistry* 43 (2): 397–403. [https://doi.org/10.1016/0031-9422\(96\)00209-9](https://doi.org/10.1016/0031-9422(96)00209-9).

Lebot, Vincent, Dennis J. McKenna, Ed Johnston, Qun Yi Zheng, and Doug McKern. 1999. "Morphological, Phytochemical, and Genetic Variation in Hawaiian Cultivars of 'Awa (*Kava*, *Piper Methysticum*, *Piperaceae*)." *Economic Botany* 53 (4): 407–18. <https://doi.org/10.1007/bf02866720>.

Lebot, Vincent, Serge Michalet, and Laurent Legendre. 2019. "Kavalactones and Flavokavins Profiles Contribute to Quality Assessment of Kava (*Piper Methysticum* G. Forst.), the Traditional Beverage of the Pacific." *Beverages* 5 (2): 34. <https://doi.org/10.3390/beverages5020034>.

Lebot, Vincent, and Patricia Siméoni. 2004. "Is the Quality of Kava (*Piper Methysticum* Forst. F.) Responsible for Different Geographical Patterns?" *Ethnobotany Research and Applications*. <https://scholarspace.manoa.hawaii.edu/handle/10125/135>.

Lehrl, Siegfried. 2004. "Clinical Efficacy of Kava Extract WS 1490 in Sleep Disturbances Associated with Anxiety Disorders. Results of a Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial." *Journal of Affective Disorders* 78 (2): 101–10. [https://doi.org/10.1016/s0165-0327\(02\)00238-0](https://doi.org/10.1016/s0165-0327(02)00238-0).

Lemert, E. M. 1967. "Secular Use of Kava in Tonga." *Quarterly Journal of Studies on Alcohol* 28 (2): 328–41. <https://www.ncbi.nlm.nih.gov/pubmed/6049173>.

———. 1976. "Koni, Kona, Kava. Orange-Beer Culture of the Cook Islands." *Journal of Studies on Alcohol* 37 (5): 565–85. <https://doi.org/10.15288/jsa.1976.37.565>.

Lester, R. H. 1941. "Kava Drinking in Vitilevu, Fiji." *Oceania; a Journal Devoted to the Study of the Native Peoples of Australia, New Guinea, and the Islands of the Pacific* 12 (2): 97–121. <http://www.jstor.org/stable/40327938>.

Leung, Nicola. 2004. "Acute Urinary Retention Secondary to Kava Ingestion." *Emergency Medicine Australasia: EMA* 16 (1): 94. <https://doi.org/10.1111/j.1742-6723.2004.00554.x>.

Lhuissier, Tiphaine, Pierre-Edouard Mercier, Serge Michalet, Vincent Lebot, and Laurent Legendre. 2017. "Colorimetric Assessment of Kava (*Piper Methysticum* Forst.) Quality." *Journal of Food Composition and Analysis: An Official Publication of the United Nations University, International Network of Food Data Systems* 59 (June): 27–34. <https://doi.org/10.1016/j.jfca.2017.02.005>.

Li, Juan, Lei Zheng, Mi Yan, Jing Wu, Yongqing Liu, Xiaona Tian, Wen Jiang, Lu Zhang, and Rongmei Wang. 2020. "Activity and Mechanism of Flavokawain A in Inhibiting P-Glycoprotein Expression in Paclitaxel Resistance of Lung Cancer." *Oncology Letters* 19 (1): 379–87. <https://doi.org/10.3892/ol.2019.11069>.

Li, Xuesen, Zhongbo Liu, Xia Xu, Christopher A. Blair, Zheng Sun, Jun Xie, Michael B. Lilly, and Xiaolin Zi. 2012. "Kava Components down-Regulate Expression of AR and AR Splice Variants and Reduce Growth in Patient-Derived Prostate Cancer Xenografts in Mice." *PloS One* 7 (2): e31213. <https://doi.org/10.1371/journal.pone.0031213>.

Li, Xuesen, Xia Xu, Tao Ji, Zhongbo Liu, Mai Gu, Bang H. Hoang, and Xiaolin Zi. 2014. "Dietary Feeding of Flavokawain A, a Kava Chalcone, Exhibits a Satisfactory Safety Profile and Its Association with Enhancement of Phase II Enzymes in Mice." *Toxicology Reports* 1: 2–11. <https://doi.org/10.1016/j.toxrep.2014.02.002>.

Li, Xuesen, Noriko N. Yokoyama, Saiyang Zhang, Lina Ding, Hong-Min Liu, Michael B. Lilly, Dan Mercola, and Xiaolin Zi. 2015. "Flavokawain A Induces deNEDDylation and Skp2 Degradation Leading to Inhibition of Tumorigenesis and Cancer Progression in the TRAMP Transgenic Mouse Model." *Oncotarget* 6 (39): 41809–24. <https://doi.org/10.18632/oncotarget.6166>.

Li, Yan, Hu Mei, Qianguo Wu, Suhui Zhang, Jia-Long Fang, Leming Shi, and Lei Guo. 2011. "Methysticin and 7,8-Dihydromethysticin Are Two Major Kavalactones in Kava Extract to Induce CYP1A1." *Toxicological Sciences: An Official Journal of the Society of Toxicology* 124 (2): 388–99. <https://doi.org/10.1093/toxsci/kfr235>.

Ligresti, Alessia, Rosaria Villano, Marco Allarà, István Ujváry, and Vincenzo Di Marzo. 2012. "Kavalactones and the Endocannabinoid System: The Plant-Derived Yangonin Is a Novel CB₁ Receptor Ligand." *Pharmacological Research: The Official Journal of the Italian Pharmacological Society* 66 (2): 163–69. <https://doi.org/10.1016/j.phrs.2012.04.003>.

Lim, Steven T. S., Klaus Dragull, Chung-Shih Tang, Harry C. Bittenbender, Jimmy T. Efirid, and Pratibha V. Nerurkar. 2007. "Effects of Kava Alkaloid, Pipermethystine, and Kavalactones on Oxidative Stress and Cytochrome P450 in F-344 Rats." *Toxicological Sciences: An Official Journal of the Society of Toxicology* 97 (1): 214–21. <https://doi.org/10.1093/toxsci/kfm035>.

Lin, Chien-Tsong, K. Jayabal Senthil Kumar, Yen-Hsueh Tseng, Zi-Jie Wang, Mu-Yun Pan, Jun-Hong Xiao, Shih-Chang Chien, and Sheng-Yang Wang. 2009. "Anti-Inflammatory Activity of Flavokawain B from *Alpinia Pricei* Hayata." *Journal of Agricultural and Food Chemistry* 57 (14): 6060–65. <https://doi.org/10.1021/jf900517d>.

Lindstrom, Lamont. 2009. "Kava Pirates in Vanuatu?" *International Journal of Cultural Property* 16 (03): 291–308. <https://doi.org/10.1017/S0940739109990208>.

Liu, Ying, Jensen A. Lund, Susan J. Murch, and Paula N. Brown. 2018. "Single-Lab Validation for Determination of Kavalactones and Flavokavains in Piper Methysticum (Kava)." *Planta Medica* 84 (16): 1213–18. <https://doi.org/10.1055/a-0637-2400>.

Liu, Zhongbo, Xuesen Li, Anna Simoneau, and Xiaolin Zi. 2010. "Abstract 5678: Kavalactone Yangonin Induces Autophagy, Inhibits TSC-Mediated Translation Initiation and Acts Synergistically with a Kava Chalcone Flavokawain A on Growth Inhibition in Bladder Cancer UMUC-3 Cells." *Cancer Research* 70 (8 Supplement): 5678–5678. <https://doi.org/10.1158/1538-7445.AM10-5678>.

Liu, Zhongbo, Xia Xu, Xuesen Li, Shuman Liu, Anne R. Simoneau, Feng He, Xue-Ru Wu, and Xiaolin Zi. 2013. "Kava Chalcone, Flavokawain A, Inhibits Urothelial Tumorigenesis in the UPII-SV40T Transgenic Mouse Model." *Cancer Prevention Research* 6 (12): 1365–75. <https://doi.org/10.1158/1940-6207.CAPR-13-0219>.

Loew, D., and G. Franz. 2003. "Quality Aspects of Traditional and Industrial Kava-Extracts." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 10 (6-7): 610–12. <https://doi.org/10.1078/094471103322331638>.

Lopez-Avila, Viorica, and Janet Benedicto. 1997. "Supercritical Fluid Extraction of Kava Lactones from Piper Methysticum (Kava) Herb." *Journal of High Resolution Chromatography* 20: 555–59. <https://doi.org/10.1002/jhrc.1240201007>.

Lopez-Avila, Viorica, and George Yefchak. 2009. "Identification of Compounds in Commercial Kava Extracts by Gas Chromatography with Electron Ionization High-Resolution Mass Spectrometry." *The Open Analytical Chemistry Journal* 3 (1): 22–31. <https://doi.org/10.2174/1874065000903010022>.

Lüde, Saskia, Michael Török, Sandy Dieterle, René Jäggi, Karin Berger Büter, and Stephan Krähenbühl. 2008. "Hepatocellular Toxicity of Kava Leaf and Root Extracts." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 15 (1-2): 120–31. <https://doi.org/10.1016/j.phymed.2007.11.003>.

Luders, David. 1996. "LEGEND AND HISTORY: DID THE VANUATU-TONGA KAVA TRADE CEASE IN A.D. 1447?" *The Journal of the Polynesian Society. Polynesian Society* 105 (3): 287–310. <http://www.jstor.org/stable/20706669>.

Lynch, John. 1996. "KAVA-DRINKING IN SOUTHERN VANUATU: MELANESIAN DRINKERS, POLYNESIAN ROOTS." *The Journal of the Polynesian Society. Polynesian Society* 105 (1): 27–40.
<http://www.jstor.org/stable/20706644>.

———. 2002. "Potent Roots and the Origin of Kava." *Oceanic Linguistics* 41 (2): 493–513.
<https://doi.org/10.2307/3623318>.

Ma, Yuzhong, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester, and Bingfang Yan. 2004. "Desmethoxyyangonin and Dihydromethysticin Are Two Major Pharmacological Kavalactones with Marked Activity on the Induction of CYP3A23." *Drug Metabolism and Disposition: The Biological Fate of Chemicals* 32 (11): 1317–24.
<https://doi.org/10.1124/dmd.104.000786>.

Madhavaram, H., T. Patel, and C. Kyle. 2020. "Kavain Interference with Amphetamine Immunoassay." *Journal of Analytical Toxicology*, December. <https://doi.org/10.1093/jat/bkaa178>.

Magura, E. I., M. V. Kopanitsa, J. Gleitz, T. Peters, and O. A. Krishtal. 1997. "Kava Extract Ingredients, (–)-Methysticin and (±)-Kavain Inhibit Voltage-Operated Na⁺-Channels in Rat CA1 Hippocampal Neurons." *Neuroscience*. [https://doi.org/10.1016/s0306-4522\(97\)00177-2](https://doi.org/10.1016/s0306-4522(97)00177-2).

Malsch, U., and M. Kieser. 2001. "Efficacy of Kava-Kava in the Treatment of Non-Psychotic Anxiety, Following Pretreatment with Benzodiazepines." *Psychopharmacology* 157 (3): 277–83.
<https://doi.org/10.1007/s002130100792>.

Maneze, Della, Anau Speizer, Noeline Dalton, and Sarah Dennis. 2008. "A Descriptive Study of Kava Use among Tongan Men in Macarthur, Sydney South West." *Australian and New Zealand Journal of Public Health* 32 (4): 314–16. <https://doi.org/10.1111/j.1753-6405.2008.00246.x>.

Martin, Amanda C., Ed Johnston, Chengguo Xing, and Adrian D. Hegeman. 2014. "Measuring the Chemical and Cytotoxic Variability of Commercially Available Kava (Piper Methysticum G. Forster)." *PloS One* 9 (11): e111572. <https://doi.org/10.1371/journal.pone.0111572>.

Mathews, J. D., M. D. Riley, L. Fejo, E. Munoz, N. R. Milns, I. D. Gardner, J. R. Powers, E. Ganygulpa, and B. J. Gununuwawuy. 1988. "Effects of the Heavy Usage of Kava on Physical Health: Summary of a Pilot Survey in an Aboriginal Community." *The Medical Journal of Australia* 148 (11): 548–55.
<https://doi.org/10.5694/j.1326-5377.1988.tb93809.x>.

Mathews, James M., Amy S. Etheridge, and Sherry R. Black. 2002. "Inhibition of Human Cytochrome P450 Activities by Kava Extract and Kavalactones." *Drug Metabolism and Disposition: The Biological Fate of Chemicals* 30 (11): 1153–57. <https://doi.org/10.1124/dmd.30.11.1153>.

Mathews, James M., Amy S. Etheridge, John L. Valentine, Sherry R. Black, Donna P. Coleman, Purvi Patel, James So, and Leo T. Burka. 2005. "Pharmacokinetics and Disposition of the Kavalactone Kawain: Interaction with Kava Extract and Kavalactones in Vivo and in Vitro." *Drug Metabolism and Disposition: The Biological Fate of Chemicals* 33 (10): 1555–63. <https://doi.org/10.1124/dmd.105.004317>.

Mcdonald, David, and Anit A. Jowit T. 2000. "Kava in the Pacific Islands: A Contemporary Drug of Abuse?" *Drug and Alcohol Review* 19: 217.

Merlin, Mark, and William Raynor. 2005. "Kava Cultivation, Native Species Conservation, and Integrated Watershed Resource Management on Pohnpei Island." *Pacific Science* 59 (2): 241–60. <https://doi.org/10.1353/psc.2005.0024>.

Meseguer, Elena, Rocio Taboada, Vicenta Sánchez, María Angeles Mena, Victor Campos, and Justo García De Yébenes. 2002. "Life-Threatening Parkinsonism Induced by Kava-Kava." *Movement Disorders: Official Journal of the Movement Disorder Society* 17 (1): 195–96. <https://doi.org/10.1002/mds.1268>.

Meyer, H. J. 1965. "Antagonistic Effects of Genuine Kava-Pyrans in Experimental Inflammation and Fever." *Klinische Wochenschrift* 43: 469–70. <https://doi.org/10.1007/BF01483859>.

Mikell, J. R., B. T. Schaneberg, and I. A. Khan. 2003. "Isolation and Purification of Kava Lactones by High Performance Centrifugal Partition Chromatography." *Journal of Liquid Chromatography & Related Technologies* 26 (18): 3069–74. <https://doi.org/10.1081/JLC-120025423>.

Mills, Edward, Rana Singh, Cory Ross, Edzard Ernst, and Joel G. Ray. 2003. "Sale of Kava Extract in Some Health Food Stores." *CMAJ: Canadian Medical Association Journal = Journal de l'Association Médicale Canadienne* 169 (11): 1158–59. <https://www.ncbi.nlm.nih.gov/pubmed/14638649>.

Mills, S. Y., B. Steinhoff, and ESCOP. 2003. "Kava-Kava: A Lesson for the Phytomedicine Community." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 10 (2-3): 261–62. <https://doi.org/10.1078/094471103321660003>.

Mohanty, Manoranjan. 2017. "Fiji Kava: Production, Trade, Role and Challenges." *The Journal of Pacific Studies* 37 (1): 5–30.

Moulds, Robert F. W., and Joji Malani. 2003. "Kava: Herbal Panacea or Liver Poison?" *The Medical Journal of Australia* 178 (9): 451–53. <https://doi.org/10.5694/j.1326-5377.2003.tb05289.x>.

Mückler, Hermann. 2013. "Chiefs, Coups and Kava: Conflicts and Conflict Resolution in Fiji." <http://www.hermann-mueckler.com/pdf/Communi+Conflict.pdf>.

Mulholland, Patrick J., and Mark A. Prendergast. 2002. "Post-Insult Exposure to (+/-) Kavain Potentiates N-Methyl-D-Aspartate Toxicity in the Developing Hippocampus." *Brain Research* 945 (1): 106–13.

[https://doi.org/10.1016/s0006-8993\(02\)02745-2](https://doi.org/10.1016/s0006-8993(02)02745-2).

Münste TF, Heinze HJ, Matzke M, Steitz J. 1993. "Effects of Oxazepam and an Extract of Kava Roots (*Piper Methysticum*) on Event-Related Potentials in a Word Recognition Task." *Neuropsychobiology* 27 (1): 46–53. <https://doi.org/10.1159/000118952>.

Murphy, J. M. 1999. "Preoperative Considerations with Herbal Medicines." *AORN Journal* 69 (1): 173–75, 177–78, 180–83. [https://doi.org/10.1016/s0001-2092\(06\)62767-1](https://doi.org/10.1016/s0001-2092(06)62767-1).

Murray, Michael. 2012. "Toxicological Actions of Plant-Derived and Anthropogenic Methylenedioxyphenyl-Substituted Chemicals in Mammals and Insects." *Journal of Toxicology and Environmental Health. Part B, Critical Reviews* 15 (6): 365–95. <https://doi.org/10.1080/10937404.2012.705105>.

Musselmann B & Cappellaro. 2015. "Kava Kava." *Zeitschrift Für Komplementärmedizin* 07 (03): 44–45. <https://doi.org/10.1055/s-0035-1554957>.

Narayanapillai, Sreekanth C., Silvia Balbo, Pablo Leitzman, Alex E. Grill, Pramod Upadhyaya, Ahmad Ali Shaik, Bo Zhou, et al. 2014. "Dihydromethysticin from Kava Blocks Tobacco Carcinogen 4-(methylnitrosamino)-1-(3-Pyridyl)-1-Butanone-Induced Lung Tumorigenesis and Differentially Reduces DNA Damage in A/J Mice." *Carcinogenesis* 35 (10): 2365–72. <https://doi.org/10.1093/carcin/bgu149>.

Narayanapillai, Sreekanth C., Pablo Leitzman, M. Gerard O'Sullivan, and Chengguo Xing. 2014. "Flavokawains a and B in Kava, Not Dihydromethysticin, Potentiate Acetaminophen-Induced Hepatotoxicity in C57BL/6 Mice." *Chemical Research in Toxicology* 27 (10): 1871–76. <https://doi.org/10.1021/tx5003194>.

National Institute of Health. 2018. "Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Kava Kava." In *LiverTox: Clinical and Research Information on Drug- Induced Liver Injury*. NIH.

Newell, W. H. 1947. "THE KAVA CEREMONY IN TONGA." *The Journal of the Polynesian Society*. *Polynesian Society* 56 (4): 364–417. <http://www.jstor.org/stable/20703131>.

Ngirasowei, J., and J. Malani. 1998. "The Relationship between Sakau (kava) and Gastritis." *Pacific Health Dialog* 5 (2): 266–67. <http://pacifichealthdialog.org.fj/Volume205/No220The20Health20of20Native20Hawaiiians/Case20Reports20and20Short20Communications/The20relationship20between20Sakau.pdf>.

Noor, Neveen A. 2010. "Anxiolytic Action and Safety of Kava: Effect on Rat Brain Acetylcholinesterase Activity and Some Serum Biochemical Parameters." *African Journal of Pharmacy and Pharmacology* 4 (11): 823–28. <http://dx.doi.org/>.

Northern Territory Government. 2020. "Penalty Units." Northern Territory Government. June 22, 2020. <https://justice.nt.gov.au/attorney-general-and-justice/units-and-amounts/penalty-units>.

Norton, S. A., and P. Ruze. 1994. "Kava Dermopathy." *Journal of the American Academy of Dermatology* 31 (1): 89–97. [https://doi.org/10.1016/s0190-9622\(94\)70142-3](https://doi.org/10.1016/s0190-9622(94)70142-3).

Nosa, Vili, and Malakai Ofanoa. 2009. "The Social, Cultural and Medicinal Use of Kava for Twelve Tongan Born Men Living in Auckland, New Zealand." *Pacific Health Dialog* 15 (1): 96–102. <https://www.ncbi.nlm.nih.gov/pubmed/19585739>.

O'hara, Maureen J., William J. Kinnard, and Joseph P. Buckley. 1965. "Preliminary Characterization of Aqueous Extracts of Piper Methysticum (Kava, Kawa Kawa)." *J Pharm Sci.* 54 (7): 1021–25. <https://doi.org/10.1002/jps.2600540715>.

Ofanoa, Malakai, Stephen Buetow, Samuela Ofanoa, Peter Huggard, Janine Paynter, and Vili Nosa. 2020. "Reasons for and Impacts of Kava Use by Tongan Men in Kava Clubs in Auckland and Tonga." *Social Sciences* 9 (2): 56–60. <https://pdfs.semanticscholar.org/17e2/4e08a5f53d273c78660f5181125db790e8ab.pdf>.

Olsen, Line R., Mark P. Grillo, and Christian Skonberg. 2011. "Constituents in Kava Extracts Potentially Involved in Hepatotoxicity: A Review." *Chemical Research in Toxicology* 24 (7): 992–1002. <https://doi.org/10.1021/tx100412m>.

Ooi, Soo Liang, Penny Henderson, and Sok Cheon Pak. 2018. "Kava for Generalized Anxiety Disorder: A Review of Current Evidence." *Journal of Alternative and Complementary Medicine* 24 (8): 770–80. <https://doi.org/10.1089/acm.2018.0001>.

Orcherton, Dan F. 2011. "Forging Fijian Camaraderie: The Cultural Significance and Social Uses of Kava (yaqona)(Piper Methysticum Forst. F) in Three Upper Watershed Communities in North Western Viti Levu (Fiji Islands)." *Journal of South Pacific Agriculture*, 19. https://www.academia.edu/download/37954917/JOSPA_Vol_15_nos__1__2_2011.pdf#page=23.

Pantano, Flaminia, Roberta Tittarelli, Giulio Mannocchi, Simona Zaami, Serafino Ricci, Raffaele Giorgetti, Daniela Terranova, Francesco P. Busardò, and Enrico Marinelli. 2016. "Hepatotoxicity Induced by 'the 3Ks': Kava, Kratom and Khat." *International Journal of Molecular Sciences* 17 (4): 580. <https://doi.org/10.3390/ijms17040580>.

Parker, Jo-Anne, Thomas T. Kurien, and Clare Huppatz. 2014. "Hepatitis A Outbreak Associated with Kava Drinking." *Communicable Diseases Intelligence Quarterly Report* 38 (1): E26–28. <https://www.ncbi.nlm.nih.gov/pubmed/25409352>.

Parkman, Cynthia A. 2002. "Another FDA Warning: Kava Supplements." *The Case Manager* 13 (4): 26–28. <https://doi.org/10.1067/mcm.2002.126437>.

Patra, Kunal K., and C. Edward Coffey. 2004. "Implications of Herbal Alternative Medicine for Electroconvulsive Therapy." *The Journal of ECT* 20 (3): 186–94. <https://doi.org/10.1097/00124509-200409000-00011>.

Perez, Juan, and James F. Holmes. 2005. "Altered Mental Status and Ataxia Secondary to Acute Kava Ingestion." *The Journal of Emergency Medicine* 28 (1): 49–51. <https://doi.org/10.1016/j.jemermed.2004.10.003>.

Pescitelli, G., A. R. Bilia, M. C. Bergonzi, F. F. Vincieri, and L. Di Bari. 2010. "Cyclodextrins as Carriers for Kavalactones in Aqueous Media: Spectroscopic Characterization of (S)-7,8-Dihydrokavain and Beta-Cyclodextrin Inclusion Complex." *Journal of Pharmaceutical and Biomedical Analysis* 52 (4): 479–83. <https://doi.org/10.1016/j.jpba.2010.01.037>.

Peterman, Kaeleigh, and Emily Reynolds. 2019. "Kava-Induced Ichthyosis." *Journal of the Dermatology Nurses' Association* 11 (6): 280. <https://doi.org/10.1097/JDN.0000000000000503>.

Petersen, Glenn. 1995. "The Complexity of Power, the Subtlety of Kava." *Canberra Anthropology* 18 (1-2): 34–60. <https://doi.org/10.1080/03149099509508408>.

Petersen, Greg E., Yijin Tang, and Christine Fields. 2019. "Chemical and in Vitro Toxicity Analysis of a Supercritical Fluid Extract of Kava Kava (Piper Methysticum)." *Journal of Ethnopharmacology* 235 (May): 301–8. <https://doi.org/10.1016/j.jep.2019.01.032>.

PHAMA. 2018. *FIJI KAVA VALUE CHAIN ANALYSIS*. Australian Government and New Zealand Government.

Philibert, Jean-Marc. 2010. "The Politics of Tradition: Toward a Generic Culture in Vanuatu." *Mankind* 16 (1): 1–12. <https://doi.org/10.1111/j.1835-9310.1986.tb01274.x>.

Pinner, Keanu D., Christina T. K. Wales, Rachel A. Gristock, Hoa T. Vo, Nadine So, and Aaron T. Jacobs. 2016. "Flavokawains A and B from Kava (Piper Methysticum) Activate Heat Shock and Antioxidant Responses and Protect against Hydrogen Peroxide-Induced Cell Death in HepG2 Hepatocytes." *Pharmaceutical Biology* 54 (9): 1503–12. <https://doi.org/10.3109/13880209.2015.1107104>.

Pittler, M. H., and E. Ernst. 2003. "Kava Extract versus Placebo for Treating Anxiety." *Cochrane Database of Systematic Reviews*, no. 1. <https://doi.org/10.1002/14651858.CD003383>.

Pluskal, Tomáš, Michael P. Torrens-Spence, Timothy R. Fallon, Andrea De Abreu, Cindy H. Shi, and Jing-Ke Weng. 2019. "The Biosynthetic Origin of Psychoactive Kavalactones in Kava." *Nature Plants* 5 (8):

867–78. <https://doi.org/10.1038/s41477-019-0474-0>.

Pollastri, Michael P., Adrian Whitty, Jamie Cassidy Merrill, Xiaoren Tang, Trent D. Ashton, and Salomon Amar. 2009. "Identification and Characterization of Kava-Derived Compounds Mediating TNF-Alpha Suppression." *Chemical Biology & Drug Design* 74 (2): 121–28. <https://doi.org/10.1111/j.1747-0285.2009.00838.x>.

Pollock, Nancy J. 1991. "The Abandoned Narcotic: Kava and Cultural Instability in Melanesia. Ron Brunton, Jack Goody." *American Anthropologist* 93 (4): 1024–25. <https://doi.org/10.1525/aa.1991.93.4.02a00910>.

———. 1995. "The Power of Kava." *Canberra Anthropology* 18 (1-2): 1–19. <https://doi.org/10.1080/03149099509508406>.

———. 2009. "Sustainability of the Kava Trade." *The Contemporary Pacific* 21 (2): 265–97. <https://doi.org/10.1353/cp.0.0070>.

Prasad, Naren, and Shiu Raj. 2006. "The Perils of Unmanaged Export Growth: The Case of Kava in Fiji." *International Journal of Entrepreneurship & Small Business* 19 (4): 381–93. <https://doi.org/10.1080/08276331.2006.10593378>.

Prescott, J. 1990. "Kava Use in Australia." *Drug and Alcohol Review* 9 (4): 325–28. <https://doi.org/10.1080/09595239000185451>.

Prescott, J., D. Jamieson, N. Emdur, and P. Duffield. 1993. "Acute Effects of Kava on Measures of Cognitive Performance, Physiological Function and Mood." *Drug and Alcohol Review* 12 (1): 49–57. <https://doi.org/10.1080/09595239300185731>.

Prinsloo, Denise, Sandra van Dyk, Anél Petzer, and Jacobus P. Petzer. 2019. "Monoamine Oxidase Inhibition by Kavalactones from Kava (*Piper Methysticum*)." *Planta Medica* 85 (14-15): 1136–42. <https://doi.org/10.1055/a-1008-9491>.

Puppala M, Narayanapillai SC, Leitzman P, Sun H, Upadhyaya P, O'Sullivan MG, Hecht SS, Xing C. 2017. "Pilot in Vivo Structure-Activity Relationship of Dihydromethysticin in Blocking 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone-Induced O 6-Methylguanine and Lung Tumor in A/J Mice." *Journal of Medicinal Chemistry* 28 (60): 7935–40. <https://doi.org/10.1021/acs.jmedchem.7b00921>.

R. I. Davis, J. F. Brown. 1999. "Kava (*Piper Methysticum*) in the South Pacific: Its Importance, Methods of Cultivation, Cultivars, Diseases and Pests." *Australian Centre for International Agricultural Research*.

Raduege, Kevin M., James F. Kleshinski, J. Victor Ryckman, and John E. Tetzlaff. 2004. "Anesthetic Considerations of the Herbal, Kava." *Journal of Clinical Anesthesia* 16 (4): 305–11.

<https://doi.org/10.1016/j.jclinane.2003.08.009>.

Rasmussen, Phil. 1999. "KAVA (Piper Methysticum) - A REVIEW.pdf." , Phytomed Medicinal Herbs Ltd, Auckland. [https://www.phytomed.co.nz/site/phytomed/KAVA%20\(Piper%20methysticum\)%20-%20A%20REVIEW.pdf](https://www.phytomed.co.nz/site/phytomed/KAVA%20(Piper%20methysticum)%20-%20A%20REVIEW.pdf).

"REPORT ON KAVA ANALYSIS 2012-2015 (JULY)." n.d. Accessed May 3, 2021.
<https://brusselsbriefings.files.wordpress.com/2016/05/report-on-kava-analysis-2012-2015.pdf>.

Rivers, Z., C. Xing, and Sjm Naranayanapillai. 2016. "Kava as a Pharmacotherapy of Anxiety Disorders: Promises and Concerns." *Medicinal Chemistry* 6: 81–87.

Robinson, Daniel, Margaret Raven, Elizabeth Makin, Donna Kalfatak, Francis Hickey, and Trinison Tari. 2021. "Legal Geographies of Kava, Kastom and Indigenous Knowledge: Next Steps under the Nagoya Protocol." *Geoforum; Journal of Physical, Human, and Regional Geosciences* 118 (January): 169–79.
<https://doi.org/10.1016/j.geoforum.2020.11.001>.

Robinson, Valerie, Wilma F. Bergfeld, Donald V. Belsito, Curtis D. Klaassen, James G. Marks, Ronald C. Shank, Thomas J. Slaga, Paul W. Snyder, and F. Alan Andersen. 2009. "Final Report on the Safety Assessment of Piper Methysticum Leaf/Root/Stem Extract and Piper Methysticum Root Extract." *International Journal of Toxicology*. <https://doi.org/10.1177/10915818093509341>.

Rogers, Herbert C. Medical Record. 1886. "FLUID EXTRACT OF KAVA KAVA IN THE TREATMENT OF GONORRHOEA." *New York* 29 (19): 1866.
<https://search.proquest.com/openview/0d47a7f136a2e797296e55134f836396/1?pq-origsite=gscholar&cbl=40146>.

Rowe, A., R. Narlawar, P. W. Groundwater, and I. Ramzan. 2011. "Kavalactone Pharmacophores for Major Cellular Drug Targets." *Mini Reviews in Medicinal Chemistry* 11 (1): 79–83.
<https://doi.org/10.2174/138955711793564088>.

Rowe, Anthony, Lillian Yuan Zhang, and Iqbal Ramzan. 2011. "Toxicokinetics of Kava." *Advances in Pharmacological Sciences* 2011 (March): 326724. <https://doi.org/10.1155/2011/326724>.

Russmann, Stefan, Yann Barguil, Pierre Cabalion, Marina Kritsanida, Daniel Duhet, and Bernhard H. Lauterburg. 2003. "Hepatic Injury due to Traditional Aqueous Extracts of Kava Root in New Caledonia." *European Journal of Gastroenterology & Hepatology* 15: 1033–36.
<https://doi.org/10.1097/01.meg.0000085464.12407.7b>.

Ruze, P. 1990. "Kava-Induced Dermopathy: A Niacin Deficiency?" *The Lancet* 335 (8703): 1442–45.
[https://doi.org/10.1016/0140-6736\(90\)91458-m](https://doi.org/10.1016/0140-6736(90)91458-m).

Rychetnik, Lucie, and Christine M. Madronio. 2011. "The Health and Social Effects of Drinking Water-Based Infusions of Kava: A Review of the Evidence." *Drug and Alcohol Review* 30 (1): 74–83. <https://doi.org/10.1111/j.1465-3362.2010.00184.x>.

Saeed, S. Y. Atezaz, Richard M. Bloch, and Diana J. Antonacci. 2007. "Herbal and Dietary Supplements for Treatment of Anxiety Disorders." *Am Fam Physician* 15 (76): 549–56. <https://www.aafp.org/afp/2007/0815/p549.html>.

Saletu, B., J. Grünberger, L. Linzmayer, and P. Anderer. 1989. "EEG-Brain Mapping, Psychometric and Psychophysiological Studies on Central Effects of Kavain - a Kava Plant Derivative." *Human Psychopharmacology* 4 (3): 169–90. <https://doi.org/10.1002/hup.470040304>.

Saroya, Amritpal Singh, and Jaswinder Singh. 2018. "Piper Methysticum G.Forst: A Potent Antianxiety Agent." In *Pharmacotherapeutic Potential of Natural Products in Neurological Disorders*, 95–106. Springer, Singapore. https://doi.org/10.1007/978-981-13-0289-3_7.

Sarris, J., D. J. Kavanagh, G. Byrne, K. M. Bone, J. Adams, and G. Deed. 2009. "The Kava Anxiety Depression Spectrum Study (KADSS): A Randomized, Placebo-Controlled Crossover Trial Using an Aqueous Extract of Piper Methysticum." *Psychopharmacology* 205 (3): 399–407. <https://doi.org/10.1007/s00213-009-1549-9>.

Sarris, J., E. Laporte, A. Scholey, R. King, A. Pipingas, I. Schweitzer, and C. Stough. 2013. "Does a Medicinal Dose of Kava Impair Driving? A Randomized, Placebo-Controlled, Double-Blind Study." *Traffic Injury Prevention* 14 (1): 13–17. <https://doi.org/10.1080/15389588.2012.682233>.

Sarris, J., C. Stough, R. Teschke, Z. T. Wahid, C. A. Bousman, G. Murray, K. M. Savage, P. Mouatt, C. Ng, and I. Schweitzer. 2013. "Kava for the Treatment of Generalized Anxiety Disorder RCT: Analysis of Adverse Reactions, Liver Function, Addiction, and Sexual Effects." *Phytotherapy Research: PTR* 27 (11): 1723–28. <https://doi.org/10.1002/ptr.4916>.

Sarris, Jerome. 2018. "Herbal Medicines in the Treatment of Psychiatric Disorders: 10-Year Updated Review." *Phytotherapy Research: PTR* 32 (7): 1147–62. <https://doi.org/10.1002/ptr.6055>.

Sarris, Jerome, Jon Adams, and David J. Kavanagh. 2010. "An Explorative Qualitative Analysis of Participants' Experience of Using Kava versus Placebo in an RCT." *Australian Journal of Medical Herbalism*, January. <https://search.informit.com.au/documentSummary;dn=999237017001985;res=IELHEA>.

Sarris, Jerome, Gerard J. Byrne, Chad A. Bousman, Lachlan Cribb, Karen M. Savage, Oliver Holmes, Jenifer Murphy, et al. 2020. "Kava for Generalised Anxiety Disorder: A 16-Week Double-Blind, Randomised, Placebo-Controlled Study." *The Australian and New Zealand Journal of Psychiatry* 54 (3): 288–97. <https://doi.org/10.1177/0004867419891246>.

Sarris, Jerome, and David J. Kavanagh. 2009. "Kava and St. John's Wort: Current Evidence for Use in Mood and Anxiety Disorders." *Journal of Alternative and Complementary Medicine* 15 (8): 827–36. <https://doi.org/10.1089/acm.2009.0066>.

Sarris, Jerome, Emma LaPorte, and Isaac Schweitzer. 2011. "Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology." *The Australian and New Zealand Journal of Psychiatry* 45 (1): 27–35. <https://doi.org/10.3109/00048674.2010.522554>.

Sarris, Jerome, Erica McIntyre, and David A. Camfield. 2013. "Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence." *CNS Drugs* 27 (4): 301–19. <https://doi.org/10.1007/s40263-013-0059-9>.

Sarris, Jerome, A. Scholey, Isaac Schweitzer, Chad Bousman, Emma LaPorte, Chee Ng, Greg Murray, and C. Stough. 2012. "The Acute Effects of Kava and Oxazepam on Anxiety, Mood, Neurocognition; and Genetic Correlates: A Randomized, Placebo-Controlled, Double-Blind Study." *Human Psychopharmacology: Clinical and Experimental* 27 (3): 262–69. <https://onlinelibrary.wiley.com/doi/abs/10.1002/hup.2216>.

Sarris, Jerome, Con Stough, Chad A. Bousman, Zahra T. Wahid, Greg Murray, Rolf Teschke, Karen M. Savage, Ashley Dowell, Chee Ng, and Isaac Schweitzer. 2013. "Kava in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study." *Journal of Clinical Psychopharmacology* 33 (5): 643. <https://doi.org/10.1097/JCP.0b013e318291be67>.

Sarris, Jerome, Rolf Teschke, Con Stough, Andrew Scholey, and Isaac Schweitzer. 2011. "Re-Introduction of Kava (*Piper Methysticum*) to the EU: Is There a Way Forward?" *Planta Medica* 77 (2): 107–10. <https://doi.org/10.1055/s-0030-1250290>.

Savage, Karen M., Con K. Stough, Gerard J. Byrne, Andrew Scholey, Chad Bousman, Jenifer Murphy, Patricia Macdonald, et al. 2015. "Kava for the Treatment of Generalised Anxiety Disorder (K-GAD): Study Protocol for a Randomised Controlled Trial." *Trials* 16 (November): 493. <https://doi.org/10.1186/s13063-015-0986-5>.

Schelosky, L., C. Raffauf, K. Jendroska, and W. Poewe. 1995. "Kava and Dopamine Antagonism." *Journal of Neurology, Neurosurgery, and Psychiatry* 58 (5): 639–40. <https://doi.org/10.1136/jnnp.58.5.639>.

Scherer, J. 1998. "Kava-Kava Extract in Anxiety Disorders: An Outpatient Observational Study." *Advances in Therapy* 15 (4): 261–69. <http://dx.doi.org/>.

Schmidt, M. 2016. "Clinical Summary Kava Extract."

Schmidt, N., and B. Ferger. 2001. "Neuroprotective Effects of (+/-)-Kavain in the MPTP Mouse Model of

Parkinson's Disease." *Synapse* 40 (1): 47–54. [https://doi.org/10.1002/1098-2396\(200104\)40:1<47::AID-SYN1025>3.0.CO;2-S](https://doi.org/10.1002/1098-2396(200104)40:1<47::AID-SYN1025>3.0.CO;2-S).

Schulze, Johannes, Walter Raasch, and Claus-Peter Siegers. 2003. "Toxicity of Kava Pyrones, Drug Safety and Precautions--a Case Study." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 10 Suppl 4: 68–73. <https://doi.org/10.1078/1433-187x-00300>.

Segone, Ramoagi T., Sidonie Y. Tankeu, Weiyang Chen, Sandra Combrinck, Mathias Schmidt, and Alvaro Viljoen. 2020. "Rapid Differentiation of Piper Methysticum (kava) Plant Parts Using Single Point and Imaging Vibrational Spectroscopy." *Journal of Applied Research on Medicinal and Aromatic Plants* 16 (100235): 100235. <https://doi.org/10.1016/j.jarmap.2019.100235>.

Seitz, U., A. Schüle, and J. Gleitz. 1997. "[3H]-Monoamine Uptake Inhibition Properties of Kava Pyrones." *Planta Medica* 63 (6): 548–49. <https://doi.org/10.1055/s-2006-957761>.

Shaik, Ahmad Ali, David Lee Hermanson, and Chengguo Xing. 2009. "Identification of Methysticin as a Potent and Non-Toxic NF-kappaB Inhibitor from Kava, Potentially Responsible for Kava's Chemopreventive Activity." *Bioorganic & Medicinal Chemistry Letters* 19 (19): 5732–36. <https://doi.org/10.1016/j.bmcl.2009.08.003>.

Sharma, Ankit, Rahul Anchariya, and Chetan Dubey. 2020. "A Review on Anti-Stress Activity of Piper Methysticum." *Asian Journal of Pharmaceutical Research and Development* 8 (4): 130–36. <https://doi.org/10.22270/ajprd.v8i4.688>.

Sharma, Ankit, Mohammad Mukim, Rahul Ancheria, and Hrishab Jangid. 2021. "A Research Article on Antistress Activity of Herbal Extract Oil of Piper Methysticum on Wistar Albino." *Asian Journal of Pharmaceutical Research and Development* 9 (1): 117–29. <https://doi.org/10.22270/ajprd.v9i1.892>.

Shimoda, L. M. N., A. Showman, J. D. Baker, I. Lange, D. L. Koomoa, A. J. Stokes, R. P. Borris, and H. Turner. 2015. "Differential Regulation of Calcium Signalling Pathways by Components of Piper Methysticum ('Awa')." *Phytotherapy Research: PTR* 29 (4): 582–90. <https://doi.org/10.1002/ptr.5291>.

Shimoda, Lori M. N., Christy Park, Alexander J. Stokes, Henry Halenani Gomes, and Helen Turner. 2012. "Pacific Island 'Awa (Kava) Extracts, but Not Isolated Kavalactones, Promote Proinflammatory Responses in Model Mast Cells." *Phytotherapy Research: PTR* 26 (12): 1934–41. <https://doi.org/10.1002/ptr.4652>.

Shinomiya, Kazuaki, Toshio Inoue, Yoshiaki Utsu, Shin Tokunaga, Takayoshi Masuoka, Asae Ohmori, and Chiaki Kamei. 2005. "Effects of Kava-Kava Extract on the Sleep-Wake Cycle in Sleep-Disturbed Rats." *Psychopharmacology* 180 (3): 564–69. <https://doi.org/10.1007/s00213-005-2196-4>.

Showman, A. 2017. "CHEMICAL AND MICROBIAL ECOLOGY OF 'AWA, PIPER METHYSTICUM (G. FORST)." *Molecular Biosciences and Bioengineering*.

Showman, Angelique F., Jonathan D. Baker, Christina Linares, Chrystie K. Naeole, Robert Borris, Edward Johnston, Jerry Konanui, and Helen Turner. 2015. "Contemporary Pacific and Western Perspectives on `awa (Piper Methysticum) Toxicology." *Fitoterapia* 100 (January): 56–67. <https://doi.org/10.1016/j.fitote.2014.11.012>.

Shulgin, A. T. 1973. "The Narcotic Pepper: The Chemistry and Pharmacology of Piper Methysticum and Related Species." *Bulletin on Narcotics* 25 (2): 59–74. https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1973-01-01_2_page008.html.

Siméoni, Patricia, and Vincent Lebot. 2002. "Identification of Factors Determining Kavalactone Content and Chemotype in Kava (Piper Methysticum Forst. F.)." *Biochemical Systematics and Ecology* 30 (5): 413–24. [https://doi.org/10.1016/S0305-1978\(01\)00093-X](https://doi.org/10.1016/S0305-1978(01)00093-X).

Singh, Ranjeeta D. 2006. "POTENTIAL APPLICATION OF KAVA (Piper Methysticum F.) IN NEMATODE CONTROL." The University of the South Pacific. <http://www.uspaquatic.library.usp.ac.fj/gsdli/collect/usplibr1/index/assoc/HASHd801.dir/doc.pdf>.

Singh, Y. N. 1983. "Effects of Kava on Neuromuscular Transmission and Muscle Contractility." *Journal of Ethnopharmacology* 7 (3): 267–76. [https://doi.org/10.1016/0378-8741\(83\)90002-8](https://doi.org/10.1016/0378-8741(83)90002-8).

———. 1992. "Kava: An Overview." *Journal of Ethnopharmacology* 37 (1): 13–45. [https://doi.org/10.1016/0378-8741\(92\)90003-a](https://doi.org/10.1016/0378-8741(92)90003-a).

Singh, Yadhu N. 2005. "Potential for Interaction of Kava and St. John's Wort with Drugs." *Journal of Ethnopharmacology* 100 (1-2): 108–13. <https://doi.org/10.1016/j.jep.2005.05.014>.

———. 2009. "Kava: An Old Drug in a New World." *Cultural Critique* 71 (1): 107–28. <https://doi.org/10.1353/cul.0.0029>.

Singh, Yadhu N., and Ashwini K. Devkota. 2003. "Aqueous Kava Extracts Do Not Affect Liver Function Tests in Rats." *Planta Medica* 69 (6): 496–99. <https://doi.org/10.1055/s-2003-40658>.

Singh, Yadhu N., and Nirbhay N. Singh. 2002. "Therapeutic Potential of Kava in the Treatment of Anxiety Disorders." *CNS Drugs* 16 (11): 731–43. <https://doi.org/10.2165/00023210-200216110-00002>.

Skov, Steven J., Tanya N. Chikritzhs, Shu Q. Li, Sabine Pircher, and Steven Whetton. 2010. "How Much Is Too Much? Alcohol Consumption and Related Harm in the Northern Territory." *The Medical Journal of Australia* 193 (5): 269–72. <https://doi.org/10.5694/j.1326-5377.2010.tb03905.x>.

Smith, Katelyn, and Claudia Leiras. 2018. "The Effectiveness and Safety of Kava Kava for Treating Anxiety Symptoms: A Systematic Review and Analysis of Randomized Clinical Trials." *Complementary Therapies*

in Clinical Practice 33 (November): 107–17. <https://doi.org/10.1016/j.ctcp.2018.09.003>.

Smith, Roger M. 1983. "Kava Lactones in Piper Methysticum from Fiji." *Phytochemistry*. [https://doi.org/10.1016/0031-9422\(83\)85065-1](https://doi.org/10.1016/0031-9422(83)85065-1).

Smith, Thomas E., Mabel Djang, Alan J. Velander, C. Wade Downey, Kathleen A. Carroll, and Sophie Van Alphen. 2004. "Versatile Asymmetric Synthesis of the Kavalactones: First Synthesis of (+)-Kavain." *Organic Letters* 6 (14): 2317–20. <https://doi.org/10.1021/ol0493960>.

Sofer, Michael. 2007. "Yaqona and the Fijian Periphery Revisited." *Asia Pacific Viewpoint* 48 (2): 234–49. <https://doi.org/10.1111/j.1467-8373.2007.00342.x>.

Song, Jia-Ling, Bai-Lin Li, Yao Yuan, Ling-Hui Nie, Jia Niu, David Chiu, Zhi-Fang Xu, Jie-Wei Wu, and Sheng-Xiang Qiu. 2017. "Yanongindimers A-C, Three New Kavalactone Dimers from Piper Methysticum (kava)." *Natural Product Research* 31 (21): 2459–66. <https://doi.org/10.1080/14786419.2017.1312395>.

Sorrentino, L., A. Capasso, and M. Schmidt. 2006. "Safety of Ethanolic Kava Extract: Results of a Study of Chronic Toxicity in Rats." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 13 (8): 542–49. <https://doi.org/10.1016/j.phymed.2006.01.006>.

Sparreboom, Alex, Michael C. Cox, Milin R. Acharya, and William D. Figg. 2004. "Herbal Remedies in the United States: Potential Adverse Interactions with Anticancer Agents." *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 22 (12): 2489–2503. <https://doi.org/10.1200/JCO.2004.08.182>.

Spillane, P. K., D. A. Fisher, and B. J. Currie. 1997. "Neurological Manifestations of Kava Intoxication." *The Medical Journal of Australia* 167 (3): 172–73. <https://doi.org/10.5694/j.1326-5377.1997.tb138828.x>.

SStofer, William D. 2002. "Kavain Attenuates Vascular Contractility Through." *Planta Medica* 68: 784–89.

Stefan, U. 2009. "Toxic Hepatitis After Consumption of Traditional Kava Preparation." *Journal of Travel Medicine* 16 (1). <https://doi.org/10.1111/j.1708-8305.2008.00259.x>.

Steiner, G. G. 2000. "The Correlation between Cancer Incidence and Kava Consumption." *Hawaii Medical Journal* 59 (11): 420–22. <https://pubmed.ncbi.nlm.nih.gov/11149250>.

Stevinson, Clare, Alyson Huntley, and Edzard Ernst. 2002. "A Systematic Review of the Safety of Kava Extract in the Treatment of Anxiety." *Drug Safety: An International Journal of Medical Toxicology and Drug Experience* 25 (4): 251–61. <https://doi.org/10.2165/00002018-200225040-00003>.

Stickel, Felix, Hans-Martin Baumüller, Karlheinz Seitz, Dimitrios Vasilakis, Gerhard Seitz, Helmut K. Seitz, and Detlef Schuppan. 2003. "Hepatitis Induced by Kava (Piper Methysticum Rhizoma)." *Journal of*

Hepatology 39 (1): 62–67. [https://doi.org/10.1016/s0168-8278\(03\)00175-2](https://doi.org/10.1016/s0168-8278(03)00175-2).

Süss, R., and P. Lehmann. 1996. "Hematogenous contact eczema cause by phytogetic drugs exemplified by kava root extract." *Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete* 47 (6): 459–61. <https://doi.org/10.1007/s001050050451>.

Tabudravu, J. N., and M. Jaspars. 2005. "Anticancer Activities of Constituents of Kava (Piper Methysticum)." *The South Pacific Journal of Natural and Applied Sciences* 23 (1): 26. <https://doi.org/10.1071/sp05005>.

Tanaka, Arisa, Nanako Hamada, Yasunori Fujita, Tomohiro Itoh, Yoshinori Nozawa, Munekazu Iinuma, and Masafumi Ito. 2010. "A Novel Kavalactone Derivative Protects against H₂O₂-Induced PC12 Cell Death via Nrf2/ARE Activation." *Bioorganic & Medicinal Chemistry* 18 (9): 3133–39. <https://doi.org/10.1016/j.bmc.2010.03.034>.

Tang, Su-Ni, Jinhui Zhang, Peixin Jiang, Palika Datta, Pablo Leitzman, M. Gerard O'Sullivan, Cheng Jiang, Chengguo Xing, and Junxuan Lü. 2016. "Gene Expression Signatures Associated with Suppression of TRAMP Prostate Carcinogenesis by a Kavalactone-Rich Kava Fraction." *Molecular Carcinogenesis* 55 (12): 2291–2303. <https://doi.org/10.1002/mc.22469>.

Tang, Xiaoren, and Salomon Amar. 2016. "Kavain Involvement in LPS-Induced Signaling Pathways." *Journal of Cellular Biochemistry* 117 (10): 2272–80. <https://doi.org/10.1002/jcb.25525>.

Tang, Yaxiong, Xuesen Li, Zhongbo Liu, Anne R. Simoneau, Jun Xie, and Xiaolin Zi. 2010. "Flavokawain B, a Kava Chalcone, Induces Apoptosis via up-Regulation of Death-Receptor 5 and Bim Expression in Androgen Receptor Negative, Hormonal Refractory Prostate Cancer Cell Lines and Reduces Tumor Growth." *International Journal of Cancer. Journal International Du Cancer* 127 (8): 1758–68. <https://doi.org/10.1002/ijc.25210>.

Tang, Yaxiong, Anne R. Simoneau, Jun Xie, Babbak Shahandeh, and Xiaolin Zi. 2008. "Effects of the Kava Chalcone Flavokawain A Differ in Bladder Cancer Cells with Wild-Type versus Mutant p53." *Cancer Prevention Research* 1 (6): 439–51. <https://doi.org/10.1158/1940-6207.CAPR-08-0165>.

Tang, Yijin, and Christine Fields. 2019. "A UHPLC-UV Method Development and Validation for Determining Kavalactones and Flavokavains in Piper Methysticum (Kava)." *Molecules (Basel, Switzerland)* 24 (7): 1245. <https://doi.org/10.3390/molecules24071245>.

Tarbah, F., H. Mahler, B. Kardel, W. Weinmann, D. Hafner, and Th Daldrup. 2003. "Kinetics of Kavain and Its Metabolites after Oral Application." *Journal of Chromatography B* 789 (1): 115–30. [https://doi.org/10.1016/S1570-0232\(03\)00046-1](https://doi.org/10.1016/S1570-0232(03)00046-1).

Tawfiq, Rasha A., Noha N. Nassar, Wafaa I. El-Eraky, and Ezzeldein S. El-Denshary. 2014. "Enhanced

Efficacy and Reduced Side Effects of Diazepam by Kava Combination." *Journal of Advertising Research* 5 (5): 587–94. <https://doi.org/10.1016/j.jare.2013.08.002>.

Taylor, Dr M., and Luseane Taufa. 1997. "Decontamination of Kava (Piper Methysticum) for in Vitro Propagation." In *International Symposium on Biotechnology of Tropical and Subtropical Species Part 2* 461, 267–74. [actahort.org](https://www.actahort.org/books/461/461_29.htm). https://www.actahort.org/books/461/461_29.htm.

Taylor, John P. 2010. "Janus and the Siren's Call: Kava and the Articulation of Gender and Modernity in Vanuatu." *The Journal of the Royal Anthropological Institute* 16 (2): 279–96. <https://doi.org/10.1111/j.1467-9655.2010.01625.x>.

Tecun, Arcia. 2017. "TONGAN KAVA: PERFORMANCE, ADAPTATION, AND IDENTITY IN DIASPORA." *None*.

Tecun, Arcia, Robert Reeves, and Marlena Wolfgramm. 2020. "The Past Before Us: A Brief History of Tongan Kava." *The Journal of the Polynesian Society*. *Polynesian Society* 129 (2): 171–92. <https://doi.org/10.15286/jps.129.2.171-192>.

Teschke, R., J. Fuchs, R. Bahre, A. Genthner, and A. Wolff. 2010. "Kava Hepatotoxicity: Comparative Study of Two Structured Quantitative Methods for Causality Assessment." *Journal of Clinical Pharmacy and Therapeutics* 35 (5): 545–63. <https://doi.org/10.1111/j.1365-2710.2009.01131.x>.

Teschke, R., W. Gaus, and D. Loew. 2003. "Kava Extracts: Safety and Risks Including Rare Hepatotoxicity." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 10 (5): 440–46. <https://doi.org/10.1078/0944-7113-00314>.

Teschke, Rolf. 2010a. "Kava Hepatotoxicity--a Clinical Review." *Annals of Hepatology* 9 (3): 251–65. [https://doi.org/10.1016/S1665-2681\(19\)31634-5](https://doi.org/10.1016/S1665-2681(19)31634-5).

———. 2010b. "Kava Hepatotoxicity: Pathogenetic Aspects and Prospective Considerations." *Liver International: Official Journal of the International Association for the Study of the Liver* 30 (9): 1270–79. <https://doi.org/10.1111/j.1478-3231.2010.02308.x>.

Teschke, Rolf, Alexander Genthner, and Albrecht Wolff. 2009. "Kava Hepatotoxicity: Comparison of Aqueous, Ethanolic, Acetonic Kava Extracts and Kava-Herbs Mixtures." *Journal of Ethnopharmacology* 123 (3): 378–84. <https://doi.org/10.1016/j.jep.2009.03.038>.

Teschke, Rolf, and Vincent Lebot. 2011. "Proposal for a Kava Quality Standardization Code." *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association* 49 (10): 2503–16. <https://doi.org/10.1016/j.fct.2011.06.075>.

Teschke, Rolf, Samuel X. Qiu, and Vincent Lebot. 2011. "Herbal Hepatotoxicity by Kava: Update on Pipermethystine, Flavokavain B, and Mould Hepatotoxins as Primarily Assumed Culprits." *Digestive and*

Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 43 (9): 676–81. <https://doi.org/10.1016/j.dld.2011.01.018>.

Teschke, Rolf, Samuel X. Qiu, Tran Dang Xuan, and Vincent Lebot. 2011. “Kava and Kava Hepatotoxicity: Requirements for Novel Experimental, Ethnobotanical and Clinical Studies Based on a Review of the Evidence.” *Phytotherapy Research: PTR* 25 (9): 1263–74. <https://doi.org/10.1002/ptr.3464>.

Teschke, Rolf, Jerome Sarris, Xaver Glass, and Johannes Schulze. 2011. “Kava, the Anxiolytic Herb: Back to Basics to Prevent Liver Injury?: Kava, back to Basics?” *British Journal of Clinical Pharmacology* 71 (3): 445–48. <https://doi.org/10.1111/j.1365-2125.2010.03775.x>.

Teschke, Rolf, Jerome Sarris, and Vincent Lebot. 2011. “Kava Hepatotoxicity Solution: A Six-Point Plan for New Kava Standardization.” *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 18 (2-3): 96–103. <https://doi.org/10.1016/j.phymed.2010.10.002>.

———. 2013. “Contaminant Hepatotoxins as Culprits for Kava Hepatotoxicity--Fact or Fiction?” *Phytotherapy Research: PTR* 27 (3): 472–74. <https://doi.org/10.1002/ptr.4729>.

Teschke, Rolf, Alexander Schwarzenboeck, and Karl-Heinz Hennermann. 2008. “Kava Hepatotoxicity: A Clinical Survey and Critical Analysis of 26 Suspected Cases.” *European Journal of Gastroenterology & Hepatology* 20 (12): 1182–93. <https://doi.org/10.1097/MEG.0b013e3283036768>.

Thompson, Richard, Willibald Ruch, and Rüdiger U. Hasenöhl. 2004. “Enhanced Cognitive Performance and Cheerful Mood by Standardized Extracts of Piper Methysticum (Kava-Kava).” *Human Psychopharmacology: Clinical and Experimental* 19 (4): 243–50. <https://onlinelibrary.wiley.com/doi/abs/10.1002/hup.581>.

Thomsen, Michael, and Mathias Schmidt. 2021. “Health Policy versus Kava (Piper Methysticum): Anxiolytic Efficacy May Be Instrumental in Restoring the Reputation of a Major South Pacific Crop.” *Journal of Ethnopharmacology* 268 (March): 113582. <https://doi.org/10.1016/j.jep.2020.113582>.

Titcomb, Margaret. 1948. “Kava in Hawaii.” *The Journal of the Polynesian Society. Polynesian Society* 57 (2): 105–71. <https://doi.org/10.2307/20703155>.

Tomlinson, Matt. 2004. “Perpetual Lament: Kava-Drinking, Christianity and Sensations of Historical Decline in Fiji.” *The Journal of the Royal Anthropological Institute* 10 (3): 653–73. <http://www.jstor.org/stable/3803799>.

———. 2006. “A CONSUMING TRADITION Kava Drinking in Fiji.” In *Consuming Tradition, Manufacturing Heritage - Global Norms and Urban Forms in the Age of Tourism*, edited by Nezar Alsayyad, 48:8–17. Routledge. <https://doi.org/10.4324/9781315011486>.

———. 2007. "Everything and Its Opposite: Kava Drinking in Fiji." *Anthropological Quarterly* 80 (4): 1065–81. <http://www.jstor.org/stable/30052773>.

———. 2019. "Is There a Relationship between Ritual and Cliché?: Indigenous Fijian Criticism of Kava Drinking." *Ethnos*, December, 1–17. <https://doi.org/10.1080/00141844.2019.1640265>.

Triolet, Julie, Ahmad Ali Shaik, Daniel D. Gallaher, Michael G. O'Sullivan, and Chengguo Xing. 2012. "Reduction in Colon Cancer Risk by Consumption of Kava or Kava Fractions in Carcinogen-Treated Rats." *Nutrition and Cancer* 64 (6): 838–46. <https://doi.org/10.1080/01635581.2012.689917>.

Tugcu, Gulcin, Hasan Kirmızıbekmez, and Ahmet Aydın. 2020. "The Integrated Use of in Silico Methods for the Hepatotoxicity Potential of Piper Methysticum." *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association* 145 (November): 111663. <https://doi.org/10.1016/j.fct.2020.111663>.

"TURMOIL AT VANUATU COMMODITIES BOARD." n.d. Accessed May 3, 2021. <http://www.pireport.org/articles/2009/04/22/turmoil-vanuatu-commodities-board>.

Turner, James W. 1986. "'The Water of Life': Kava Ritual and the Logic of Sacrifice." *Ethnology* 25 (3): 203–14. <https://doi.org/10.2307/3773584>.

Turner, James West. 2012. "LISTENING TO THE ANCESTORS: KAVA AND THE LAPITA PEOPLES." *Ethnology* 51 (1).

Tzeng, Yew-Min, and Meng-Jen Lee. 2015. "Neuroprotective Properties of Kavalactones." *Neural Regeneration Research* 10 (6): 875–77. <https://doi.org/10.4103/1673-5374.158335>.

Uebelhock, R., L. Fronke, and H-1 Schewe. 1998. "Inhibition of Platelet MAO-6 by Kava Pyrone-Enriched Extract from Piper Methysticum Forster (Kava-Kava)." *Pharmacopsychiatry* 31 (5): 187–92. <https://doi.org/10.1055/s-2007-979325>.

Ulbricht, Catherine, Ethan Basch, Heather Boon, Edzard Ernst, Paul Hammerness, David Sollars, Candy Tsourounis, Jen Woods, and Stephen Bent. 2005. "Safety Review of Kava (Piper Methysticum) by the Natural Standard Research Collaboration." *Expert Opinion on Drug Safety* 4 (4): 779–94. <https://doi.org/10.1517/14740338.4.4.779>.

Ulbricht, Catherine, Ethan Basch, Hammerness Paul, Sollars David, Basch Samuel, Heather Boon, Catherine Ulbricht, et al. 2002. "Kava Monograph." *Journal of Herbal Pharmacotherapy* 2 (4): 65–91. https://doi.org/10.1080/J157v02n04_07.

Upadhyay, Atul, Emmy Tuenter, Rizwan Ahmad, Adnan Amin, Vasiliki Exarchou, Sandra Apers, Nina Hermans, and Luc Pieters. 2014. "Kavalactones, a Novel Class of Protein Glycation and Lipid Peroxidation

Inhibitors." *Planta Medica* 80 (12): 1001–8. <https://doi.org/10.1055/s-0034-1382949>.

Urquhart, Belinda, and Neil Thomson. 2009. "Review of the Misuse of Kava among Indigenous Australians." *Australian Indigenous HealthReviews* 9 (3): 1–14.
<http://ro.ecu.edu.au/cgi/viewcontent.cgi?article=1598&context=ecuworks>.

Uzomba, N. I., Ajah Obinna, and E. C. Amaralam. 2020. "PHYTOCHEMICAL AND NUTRITIONAL COMPOSITION OF PIPER METHYSTICUM LEAVES." *World Journal of Pharmaceutical Research* 9 (3): 220–26. <https://doi.org/10.20959/wjpr20203-16848>.

Va'a, Unasa Leulu Fplise. 2010. "Indigenous Anthropology and the Kava Myth in Manu'a." *Pacific Studies* 33: 19–19. <http://ojs-dev.byuh.edu/index.php/pacific/article/download/1165/1116>.

Van, Truong Mai, Tran Dang Xuan, Truong Ngoc Minh, and Nguyen Van Quan. 2018. "Isolation and Purification of Potent Growth Inhibitors from Piper Methysticum Root." *Molecules* 23 (8).
<https://doi.org/10.3390/molecules23081907>.

Vandenbroucke, Henri, Pierre Mournet, Roger Malapa, Jean-Christophe Glaszmann, Hana Chair, and Vincent Lebot. 2015. "Comparative Analysis of Genetic Variation in Kava (Piper Methysticum) Assessed by SSR and DArT Reveals Zygotic Foundation and Clonal Diversification." *Genome / National Research Council Canada = Genome / Conseil National de Recherches Canada* 58 (1): 1–11.
<https://doi.org/10.1139/gen-2014-0166>.

Vanuatu. 2002. "Kava Act 2002." 7. Republic Of Vanuatu.
<https://biosecurity.gov.vu/images/Export/kava-act-2002.pdf>.

Visser, Edward P. 1994. "SKELETAL EVIDENCE OF KAVA USE IN PREHISTORIC FIJI." *The Journal of the Polynesian Society. Polynesian Society* 103 (3): 299–317. <http://www.jstor.org/stable/20706579>.

Volgin, Andrey, Longen Yang, Tamara Amstislavskaya, Konstantin Demin, Dongmei Wang, Dongni Yan, Jingtao Wang, et al. 2020. "DARK Classics in Chemical Neuroscience: Kava." *ACS Chemical Neuroscience*, January. <https://doi.org/10.1021/acscemneuro.9b00587>.

Volz HP, Kieser M. 1997. "Kava-Kava Extract WS 1490 versus Placebo in Anxiety Disorders--a Randomized Placebo-Controlled 25-Week Outpatient Trial." *Pharmacopsychiatry* 30 (1): 1–5.
<https://doi.org/10.1055/s-2007-979474>.

Wainiqolo, Iris, Bridget Kool, Vili Nosa, and Shanthi Ameratunga. 2015. "Is Driving under the Influence of Kava Associated with Motor Vehicle Crashes? A Systematic Review of the Epidemiological Literature." *Australian and New Zealand Journal of Public Health* 39 (5): 495–99. <https://doi.org/10.1111/1753-6405.12435>.

Walden, J., J. von Wegerer, U. Winter, M. Berger, and H. Grunze. 1997. "Effects of Kawain and Dihydromethysticin on Field Potential Changes in the Hippocampus." *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 21 (4): 697–706. [https://doi.org/10.1016/s0278-5846\(97\)00042-0](https://doi.org/10.1016/s0278-5846(97)00042-0).

Walden, Jorg, Jorg Von Wegerer, Ute Winter, and M. Berger. 1997. "Actions of Kavain and Dihydromethysticin on Ipsapirone-Induced Field Potential Changes in the Hippocampus." *HUMAN PSYCHOPHARMACOLOGY, VOL. 12*: 265–70. [https://doi.org/10.1002/\(SICI\)1099-1077\(199705/06\)12:3](https://doi.org/10.1002/(SICI)1099-1077(199705/06)12:3).

Walia, Arman, Nikta Rezakahn Khajeh, Michael Wu, Cyrus Khoyilar, and Xiaolin Zi. 2016. "Kava in Prostate Cancer Prevention and Treatment." *Complementary and Alternative Medicines in Prostate Cancer: A Comprehensive Approach*, 29. https://books.google.com/books?hl=en&lr=&id=yKSIDQAAQBAJ&oi=fnd&pg=PT230&dq=kava+DRINK&ots=h2uT5AX3HE&sig=oVdsZoh3Km_u658jMLuJtAcfB64.

Wang, Dongmei, Longen Yang, Jingtao Wang, Guojun Hu, Ziyuan Liu, Dongni Yan, Nazar Serikuly, et al. 2020. "Behavioral and Physiological Effects of Acute and Chronic Kava Exposure in Adult Zebrafish." *Neurotoxicology and Teratology* 79 (May): 106881. <https://doi.org/10.1016/j.ntt.2020.106881>.

Wang, Jun, Weiyue Qu, Harry C. Bittenbender, and Qing X. Li. 2015. "Kavalactone Content and Chemotype of Kava Beverages Prepared from Roots and Rhizomes of Isa and Mahakea Varieties and Extraction Efficiency of Kavalactones Using Different Solvents." *Journal of Food Science and Technology* 52 (2): 1164–69. <https://doi.org/10.1007/s13197-013-1047-2>.

Wang, Yi, Shainnel O. Eans, Heather M. Stacy, Sreekanth C. Narayanapillai, Abhisheak Sharma, Naomi Fujioka, Linda Haddad, Jay McLaughlin, Bonnie A. Avery, and Chengguo Xing. 2018. "A Stable Isotope Dilution Tandem Mass Spectrometry Method of Major Kavalactones and Its Applications." *PloS One* 13 (5): e0197940. <https://doi.org/10.1371/journal.pone.0197940>.

Wang, Yi, Sreekanth C. Narayanapillai, Katelyn M. Tessier, Lori G. Strayer, Pramod Upadhyaya, Qi Hu, Rick Kingston, et al. 2020. "The Impact of One-Week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-Based Carcinogenesis Risk among Active Smokers." *Cancer Prevention Research* 13 (5): 483–92. <https://doi.org/10.1158/1940-6207.CAPR-19-0501>.

Warburton, Emma, Paul L. Norris, and Heidi Goenaga-Infante. 2007. "Comparison of the Capabilities of Accelerated Solvent Extraction and Sonication as Extraction Techniques for the Quantification of Kavalactones in Piper Methysticum (Kava) Roots by High Performance Liquid Chromatography with Ultra Violet Detection." *Phytochemical Analysis: PCA* 18 (2): 98–102. <https://doi.org/10.1002/pca.955>.

Watkins, L. L., K. M. Connor, and J. R. Davidson. 2001. "Effect of Kava Extract on Vagal Cardiac Control in Generalized Anxiety Disorder: Preliminary Findings." *Journal of Psychopharmacology* 15 (4): 283–86. <https://doi.org/10.1177/026988110101500407>.

Weiss, Johanna, Alexandra Sauer, Andreas Frank, and Matthias Unger. 2005. "Extracts and Kavalactones of Piper Methysticum G. Forst (kava-Kava) Inhibit P-Glycoprotein in Vitro." *Drug Metabolism and Disposition: The Biological Fate of Chemicals* 33 (11): 1580–83. <https://doi.org/10.1124/dmd.105.005892>.

White, C. Michael. 2018. "The Pharmacology, Pharmacokinetics, Efficacy, and Adverse Events Associated With Kava." *Journal of Clinical Pharmacology* 58 (11): 1396–1405. <https://doi.org/10.1002/jcph.1263>.

Whitton, Peter A. 2004. "Response to Schmidt 'Are Kavalactones the Hepatotoxic Principle of Kava Extracts? The Pitfalls of the Glutathione Theory.'" *The Journal of Alternative and Complementary Medicine* 9 (2): 187–88. <https://doi.org/10.1089/10755530360623293>.

Whitton, Peter A., Andrew Lau, Alicia Salisbury, Julie Whitehouse, and Christine S. Evans. 2003. "Kava Lactones and the Kava-Kava Controversy." *Phytochemistry* 64 (3): 673–79. [https://doi.org/10.1016/s0031-9422\(03\)00381-9](https://doi.org/10.1016/s0031-9422(03)00381-9).

Winter, Kawika, and Will McClatchey. 2009. "The Quantum Co-Evolution Unit: An Example of 'Awa (Kava—Piper Methysticum G. Foster) in Hawaiian Culture." *Economic Botany* 63 (4): 353–62. <https://doi.org/10.1007/s12231-009-9089-0>.

Witte, Steffen, Dieter Loew, and Wilhelm Gaus. 2005. "Meta-Analysis of the Efficacy of the Acetonic Kava-Kava Extract WS1490 in Patients with Non-Psychotic Anxiety Disorders." *Phytotherapy Research: PTR* 19 (3): 183–88. <https://doi.org/10.1002/ptr.1609>.

Wruck, Christoph J., Mario E. Götz, Thomas Herdegen, Deike Varoga, Lars-Ove Brandenburg, and Thomas Pufe. 2008. "Kavalactones Protect Neural Cells against Amyloid Beta Peptide-Induced Neurotoxicity via Extracellular Signal-Regulated Kinase 1/2-Dependent Nuclear Factor Erythroid 2-Related Factor 2 Activation." *Molecular Pharmacology* 73 (6): 1785–95. <https://doi.org/10.1124/mol.107.042499>.

Wu, D., L. Yu, M. G. Nair, D. L. DeWitt, and R. S. Ramsewak. 2002. "Cyclooxygenase Enzyme Inhibitory Compounds with Antioxidant Activities from Piper Methysticum (kava Kava) Roots." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 9 (1): 41–47. <https://doi.org/10.1078/0944-7113-00068>.

Xuan, T. D., A. A. Elzaawely, M. Fukuta, and S. Tawata. 2006. "Herbicidal and Fungicidal Activities of Lactones in Kava (Piper Methysticum)." *Journal of Agricultural and Food Chemistry* 54 (3): 720–25. <https://doi.org/10.1021/jf0519461>.

Xuan, Tran Dang, Masakazu Fukuta, Ao Chang Wei, Abdelnaser Abdelghany Elzaawely, Tran Dang Khanh, and Shinkichi Tawata. 2008. "Efficacy of Extracting Solvents to Chemical Components of Kava (Piper

Methysticum) Roots." *Journal of Natural Medicines* 62 (2): 188–94. <https://doi.org/10.1007/s11418-007-0203-2>.

Yadnu, N. Singh. 1986. "A Review of the Chemistry and Pharmacology of Kava." University of Alberta. http://moana.library.usp.ac.fj/gsd/collect/kalenchits_m-moanausp/index/assoc/HASH0127.dir/doc.pdf.

Yang, Jian Xiang. 2019. "A New Kavalactone Dimer from Piper Methysticum." *Chemistry of Natural Compounds* 55 (4): 606–9. <https://doi.org/10.1007/s10600-019-02759-8>.

Yang, Xi, and William F. Salminen. 2011. "Kava Extract, an Herbal Alternative for Anxiety Relief, Potentiates Acetaminophen-Induced Cytotoxicity in Rat Hepatic Cells." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 18 (7): 592–600. <https://doi.org/10.1016/j.phymed.2011.02.006>.

Yiannis, Callisthenis, Kevin Huang, An Nhien Tran, Cathy Zeng, Emily Dao, Oliver Baselyous, Muaaz Adil Mithwani, et al. 2020. "Protective Effect of Kava Constituents in an in Vitro Model of Oral Mucositis." *Journal of Cancer Research and Clinical Oncology* 146 (7): 1801–11. <https://doi.org/10.1007/s00432-020-03253-3>.

Young, Michael W. 1995. "Kava and Christianity in Central Vanuatu: With an Appendix on the Ethnography of Kava Drinking in Nikaura, Epi." *Canberra Anthropology* 18 (1-2): 61–96. <https://www.tandfonline.com/doi/pdf/10.1080/03149099509508409>.

Yuan, Chun-Su, Lucy Dey, Anbao Wang, Sangeeta Mehendale, Jing-Tian Xie, Han H. Aung, and Michael K. Ang-Lee. 2002. "Kavalactones and Dihydrokavain Modulate GABAergic Activity in a Rat Gastric-Brainstem Preparation." *Planta Medica* 68 (12): 1092–96. <https://doi.org/10.1055/s-2002-36338>.

Yuncker, Truman George. 1940. "Kava, Its Preparation and Use." In *Proceedings of the Indiana Academy of Science*, 50:69–71. journals.iupui.edu. <https://journals.iupui.edu/index.php/ias/article/download/4715/4623>.

Zhang, Nenling, Linjing Wu, Xiang Liu, and Xiangchun Shen. 2018. "Plant-Derived Kavalactones and Their Bioactivities." *Le Medecin de Reserve* 2 (1): 20170019–20170013. <https://doi.org/10.21127/yaoyimr20170019>.

Zhang, Yidan, Yoav S. Zvi, Brian Batko, Nikolas Zaphiros, Edmond F. O'Donnell, Jichuan Wang, Kenji Sato, et al. 2018. "Down-Regulation of Skp2 Expression Inhibits Invasion and Lung Metastasis in Osteosarcoma." *Scientific Reports* 8 (1): 14294. <https://doi.org/10.1038/s41598-018-32428-9>.

Zhao, Xiaojun, Chao Su, Ruru Ren, Bo Zhang, Yingli Wang, Xiaojuan Su, Fangfang Lu, et al. 2021. "Simultaneous Determination of Both Kavalactones and Flavokawains Constituents by Different Single Marker in Kava." *Journal of Separation Science*, May. <https://doi.org/10.1002/jssc.202100198>.

Zhou, Ping, Shimon Gross, Ji-Hua Liu, Bo-Yang Yu, Ling-Ling Feng, Jan Nolte, Vijay Sharma, David Piwnicka-Worms, and Samuel X. Qiu. 2010. "Flavokawain B, the Hepatotoxic Constituent from Kava Root, Induces GSH-Sensitive Oxidative Stress through Modulation of IKK/NF-kappaB and MAPK Signaling Pathways." *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology* 24 (12): 4722–32. <https://doi.org/10.1096/fj.10-163311>.

Zi, Xiaolin, and Anne R. Simoneau. 2005. "Flavokawain A, a Novel Chalcone from Kava Extract, Induces Apoptosis in Bladder Cancer Cells by Involvement of Bax Protein-Dependent and Mitochondria-Dependent Apoptotic Pathway and Suppresses Tumor Growth in Mice." *Cancer Research* 65 (8): 3479–86. <https://doi.org/10.1158/0008-5472.CAN-04-3803>.

Zou, L., G. L. Henderson, M. R. Harkey, Y. Sakai, and A. Li. 2004. "Effects of Kava (Kava-Kava, 'Awa, Yaqona, Piper Methysticum) on c-DNA-Expressed Cytochrome P450 Enzymes and Human Cryopreserved Hepatocytes." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 11 (4): 285–94. <https://doi.org/10.1078/0944711041495263>.

Zou, Lihong, Martha R. Harkey, Gary L. Henderson, and Laura E. Dike. 2004. "Kava Does Not Display Metabolic Toxicity in a Homogeneous Cellular Assay." *Planta Medica* 70 (4): 289–92. <https://doi.org/10.1055/s-2004-818937>.

Anke, Jennifer, and Iqqbal Ramzan. 2004. "Kava Hepatotoxicity: Are We Any Closer to the Truth?" *Planta Medica* 70: 193–96. <https://doi.org/10.1055/s-2004-815533>.

Baker, Jonathan D. 2011. "Tradition and Toxicity: Evidential Cultures in the Kava Safety Debate." *Social Studies of Science* 41 (3): 361–84. <https://doi.org/10.1177/0306312710395341>.

Bauer, Rudolf, Brigitte & Kopp, and A. Nahrstedt. 2003. "Relevant Hepatotoxic Effects of Kava Still Need to Be Proven: A Statement of the Society for Medicinal Plant Research." *Planta Medica* 69 (11): 971–72. <https://doi.org/10.1055/s-2003-45140>.

Becker, Matheus William, Emerson Matheus Silva Lourençone, Alexandre Formighieri De Mello, Aline Branco, Edison Moraes Rodrigues Filho, Celso Ronaldo Blatt, Carlos Augusto Mallmann, Maurício Schneider, Rita Catalina Aquino Caregnato, and Carine Raquel Blatt. 2019. "Liver Transplantation and the Use of KAVA: Case Report." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 56 (March): 21–26. <https://doi.org/10.1016/j.phymed.2018.08.011>.

Behl, Mamta, Abraham Nyska, Rajendra S. Chhabra, Gregory S. Travlos, Laurene M. Fomby, Barney R. Sparrow, Milton R. Hejtmancik, and Po C. Chan. 2011. "Liver Toxicity and Carcinogenicity in F344/N Rats and B6C3F1 Mice Exposed to Kava Kava." *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association* 49 (11): 2820–29. <https://doi.org/10.1016/j.fct.2011.07.067>.

Brown, Amy C., Janet Onopa, Peter Holck, Pakieli Kaufusi, Derek Kabasawa, Winston J. Craig, Klaus Dragull, Arieh M. Levine, and Jonathan D. Baker. 2007. "Traditional Kava Beverage Consumption and Liver Function Tests in a Predominantly Tongan Population in Hawaii." *Clinical Toxicology* 45 (5): 549–56. <https://doi.org/10.1080/15563650701365875>.

Bujanda, L., A. Palacios, R. Silviriño, A. Sánchez, and C. Muñoz. 2002. "[Kava-induced acute icteric hepatitis]." *Gastroenterologia y hepatologia* 25 (6): 434–35. [https://doi.org/10.1016/s0210-5705\(02\)70281-1](https://doi.org/10.1016/s0210-5705(02)70281-1).

Centers for Disease Control and Prevention (CDC). 2002. "Hepatic Toxicity Possibly Associated with Kava-Containing Products--United States, Germany, and Switzerland, 1999-2002." *MMWR. Morbidity and Mortality Weekly Report* 51 (47): 1065–67. <https://www.ncbi.nlm.nih.gov/pubmed/12500906>.

Chou, Tsui-Wei, Jia-Hua Feng, Chi-Chang Huang, Ya-Wen Cheng, Shih-Chang Chien, Sheng-Yang Wang, and Lie-Fen Shyur. 2013. "A Plant Kavalactone Desmethoxyyangonin Prevents Inflammation and Fulminant Hepatitis in Mice." *PloS One* 8 (10): e77626. <https://doi.org/10.1371/journal.pone.0077626>.

Clouatre, Dallas L. 2004. "Kava Kava: Examining New Reports of Toxicity." *Toxicology Letters* 150: 85–96. <https://doi.org/10.1016/j.toxlet.2003.07.005>.

Clough, Alan R., Ross S. Bailie, and Bart Currie. 2003. "Liver Function Test Abnormalities in Users of Aqueous Kava Extracts." *Journal of Toxicology. Clinical Toxicology* 41 (6): 821–29. <https://doi.org/10.1081/clt-120025347>.

Coulter, David, Tamayo Carmen Sotheeswaran Subramaniam, Catherine Ulbricht, and World Health Organization. 2007. "Assessment of the Risk of Hepatotoxicity with Kava Products.pdf." World Health Organization.

Currie, Bart J., and Alan R. Clough. 2003. "Kava Hepatotoxicity with Western Herbal Products: Does It Occur with Traditional Kava Use?" *The Medical Journal of Australia*. mja.com.au. <https://doi.org/10.5694/j.1326-5377.2003.tb05279.x>.

Danan, Gaby, and Rolf Teschke. 2015. "RUCAM in Drug and Herb Induced Liver Injury: The Update." *International Journal of Molecular Sciences* 17 (1). <https://doi.org/10.3390/ijms17010014>.

De Smet, Peter A. G. M. 2002. "Safety Concerns about Kava Not Unique." *The Lancet*. [https://doi.org/10.1016/S0140-6736\(02\)11347-X](https://doi.org/10.1016/S0140-6736(02)11347-X).

DiSilvestro, Robert A., Wenyi Zhang, and David J. DiSilvestro. 2007. "Kava Feeding in Rats Does Not Cause Liver Injury nor Enhance Galactosamine-Induced Hepatitis." *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association* 45 (7): 1293–

1300. <https://doi.org/10.1016/j.fct.2007.01.015>.

Escher, M., J. Desmeules, E. Giostra, and G. Mentha. 2001. "Hepatitis Associated with Kava, a Herbal Remedy for Anxiety." *BMJ* 322 (7279): 139. <https://doi.org/10.1136/bmj.322.7279.139>.

Food and Agriculture Organization of the United Nations, and WHO. 2016. "Kava: A Review of the Safety of Traditional and Recreational Beverage Consumption."

Fu, Peter P., Qingsu Xia, Lei Guo, Hongtao Yu, and Po-Chuen Chan. 2008. "Toxicity of Kava Kava." *Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews* 26 (1): 89–112. <https://doi.org/10.1080/10590500801907407>.

Gow, Paul J., Nathan J. Connelly, Richard L. Hill, Peter Crowley, and Peter W. Angus. 2003. "Fatal Fulminant Hepatic Failure Induced by a Natural Therapy Containing Kava." *The Medical Journal of Australia* 178 (9): 442–43. <https://doi.org/10.5694/j.1326-5377.2003.tb05286.x>.

Humberston, C. L., J. Akhtar, and E. P. Krenzelok. 2003. "Acute Hepatitis Induced by Kava Kava." *Journal of Toxicology. Clinical Toxicology* 41 (2): 109–13. <https://doi.org/10.1081/clt-120019123>.

Jhoo, Jin-Woo, James P. Freeman, Thomas M. Heinze, Joanna D. Moody, Laura K. Schnackenberg, Richard D. Beger, Klaus Dragull, Chung-Shih Tang, and Catharina Y. W. Ang. 2006. "In Vitro Cytotoxicity of Nonpolar Constituents from Different Parts of Kava Plant (*Piper Methysticum*)." *Journal of Agricultural and Food Chemistry* 54 (8): 3157–62. <https://doi.org/10.1021/jf051853j>.

Kraft, M., T. W. Spahn, J. Menzel, N. Senninger, K. H. Dietl, H. Herbst, W. Domschke, and M. M. Lerch. 2001. "[Fulminant liver failure after administration of the herbal antidepressant Kava-Kava]." *Deutsche medizinische Wochenschrift* 126 (36): 970–72. <https://doi.org/10.1055/s-2001-16966>.

Lechtenberg, M., B. Quandt, M. Schmidt, and A. Nahrstedt. 2008. "Is the Alkaloid Pipermethystine Connected with the Claimed Liver Toxicity of Kava Products?" *Die Pharmazie* 63 (1): 71–74. <https://www.ncbi.nlm.nih.gov/pubmed/18271308>.

Li, X. Z., and I. Ramzan. 2010. "Role of Ethanol in Kava Hepatotoxicity." *Phytotherapy Research: PTR* 24 (4): 475–80. <https://doi.org/10.1002/ptr.3046>.

Lüde, Saskia, Michael Török, Sandy Dieterle, René Jäggi, Karin Berger Büter, and Stephan Krähenbühl. 2008. "Hepatocellular Toxicity of Kava Leaf and Root Extracts." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 15 (1-2): 120–31. <https://doi.org/10.1016/j.phymed.2007.11.003>.

Moulds, Robert F. W., and Joji Malani. 2003. "Kava: Herbal Panacea or Liver Poison?" *The Medical Journal of Australia* 178 (9): 451–53. <https://doi.org/10.5694/j.1326-5377.2003.tb05289.x>.

Nerurkar, Pratibha V., Klaus Dragull, and Chung-Shih Tang. 2004. "In Vitro Toxicity of Kava Alkaloid, Pipermethystine, in HepG2 Cells Compared to Kavalactones." *Toxicological Sciences: An Official Journal of the Society of Toxicology* 79 (1): 106–11. <https://doi.org/10.1093/toxsci/kfh067>.

Olsen, Line R., Mark P. Grillo, and Christian Skonberg. 2011. "Constituents in Kava Extracts Potentially Involved in Hepatotoxicity: A Review." *Chemical Research in Toxicology* 24 (7): 992–1002. <https://doi.org/10.1021/tx100412m>.

Pantano, Flaminia, Roberta Tittarelli, Giulio Mannocchi, Simona Zaami, Serafino Ricci, Raffaele Giorgetti, Daniela Terranova, Francesco P. Busardò, and Enrico Marinelli. 2016. "Hepatotoxicity Induced by 'the 3Ks': Kava, Kratom and Khat." *International Journal of Molecular Sciences* 17 (4): 580. <https://doi.org/10.3390/ijms17040580>.

"Re: Critical Analysis of Suspected Cases of Kava Hepatotoxicity: Kava Taken as Directed Is Rarely Hepatotoxic - American Botanical Council." n.d. Accessed May 10, 2021. https://www.herbalgram.org/resources/herbclip/issues/bin_368/review120381-368/.

Rowe, Anthony, Lillian Yuan Zhang, and Iqbal Ramzan. 2011. "Toxicokinetics of Kava." *Advances in Pharmacological Sciences* 2011 (March): 326724. <https://doi.org/10.1155/2011/326724>.

Russmann, S., B. H. Lauterburg, and A. Helbling. 2001. "Kava Hepatotoxicity." *Annals of Internal Medicine* 135 (1): 68–69. <https://doi.org/10.7326/0003-4819-135-1-200107030-00036>.

Russmann, Stefan, Yann Barguil, Pierre Cabalion, Marina Kritsanida, Daniel Duhet, and Bernhard H. Lauterburg. 2003. "Hepatic Injury due to Traditional Aqueous Extracts of Kava Root in New Caledonia." *European Journal of Gastroenterology & Hepatology* 15: 1033–36. <https://doi.org/10.1097/01.meg.0000085464.12407.7b>.

Schmidt, Mathias. 2003. "Are Kavalactones the Hepatotoxic Principle of Kava Extracts? The Pitfalls of the Glutathione Theory." *Journal of Alternative and Complementary Medicine* . <https://doi.org/10.1089/10755530360623284>.

Shah, Maulik, Hasan Ali, and Hisham Elgenaidi. 2019. "2338 Drug-Induced Liver Injury From Prolonged Kava Kava and Kratom Use." *Official Journal of the American College of Gastroenterology | ACG* 114 (October): S1304. <https://doi.org/10.14309/01.ajg.0000598884.08856.da>.

Showman, Angelique F., Jonathan D. Baker, Christina Linares, Chrystie K. Naeole, Robert Borris, Edward Johnston, Jerry Konanui, and Helen Turner. 2015. "Contemporary Pacific and Western Perspectives on `awa (Piper Methysticum) Toxicology." *Fitoterapia* 100 (January): 56–67. <https://doi.org/10.1016/j.fitote.2014.11.012>.

Singh, Yadhu N., and Ashwini K. Devkota. 2003. "Aqueous Kava Extracts Do Not Affect Liver Function

Tests in Rats." *Planta Medica* 69 (6): 496–99. <https://doi.org/10.1055/s-2003-40658>.

Sorrentino, L., A. Capasso, and M. Schmidt. 2006. "Safety of Ethanolic Kava Extract: Results of a Study of Chronic Toxicity in Rats." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 13 (8): 542–49. <https://doi.org/10.1016/j.phymed.2006.01.006>.

Stefan, U. 2009. "Toxic Hepatitis After Consumption of Traditional Kava Preparation." *Journal of Travel Medicine* 16 (1). <https://doi.org/10.1111/j.1708-8305.2008.00259.x>.

Stickel, Felix, Hans-Martin Baumüller, Karlheinz Seitz, Dimitrios Vasilakis, Gerhard Seitz, Helmut K. Seitz, and Detlef Schuppan. 2003. "Hepatitis Induced by Kava (Piper Methysticum Rhizoma)." *Journal of Hepatology* 39 (1): 62–67. [https://doi.org/10.1016/s0168-8278\(03\)00175-2](https://doi.org/10.1016/s0168-8278(03)00175-2).

Strahl, S., V. Ehret, H. H. Dahm, and K. P. Maier. 1998. "[Necrotizing hepatitis after taking herbal remedies]." *Deutsche medizinische Wochenschrift* 123 (47): 1410–14. <https://doi.org/10.1055/s-2007-1024196>.

Teschke, R., J. Fuchs, R. Bahre, A. Genthner, and A. Wolff. 2010. "Kava Hepatotoxicity: Comparative Study of Two Structured Quantitative Methods for Causality Assessment." *Journal of Clinical Pharmacy and Therapeutics* 35 (5): 545–63. <https://doi.org/10.1111/j.1365-2710.2009.01131.x>.

Teschke, R., W. Gaus, and D. Loew. 2003. "Kava Extracts: Safety and Risks Including Rare Hepatotoxicity." *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 10 (5): 440–46. <https://doi.org/10.1078/0944-7113-00314>.

Teschke, R., and A. Wolff. 2009. "Kava Hepatotoxicity: Regulatory Data Selection and Causality Assessment." *Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver* 41 (12): 891–901. <https://doi.org/10.1016/j.dld.2009.04.003>.

Teschke, Rolf. 2010a. "Kava Hepatotoxicity--a Clinical Review." *Annals of Hepatology* 9 (3): 251–65. [https://doi.org/10.1016/S1665-2681\(19\)31634-5](https://doi.org/10.1016/S1665-2681(19)31634-5).

———. 2010b. "Kava Hepatotoxicity: Pathogenetic Aspects and Prospective Considerations." *Liver International: Official Journal of the International Association for the Study of the Liver* 30 (9): 1270–79. <https://doi.org/10.1111/j.1478-3231.2010.02308.x>.

Teschke, Rolf, Alexander Genthner, and Albrecht Wolff. 2009. "Kava Hepatotoxicity: Comparison of Aqueous, Ethanolic, Acetonic Kava Extracts and Kava-Herbs Mixtures." *Journal of Ethnopharmacology* 123 (3): 378–84. <https://doi.org/10.1016/j.jep.2009.03.038>.

Teschke, Rolf, Samuel X. Qiu, and Vincent Lebot. 2011. "Herbal Hepatotoxicity by Kava: Update on

Pipermethystine, Flavokavain B, and Mould Hepatotoxins as Primarily Assumed Culprits.” *Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver* 43 (9): 676–81. <https://doi.org/10.1016/j.dld.2011.01.018>.

Teschke, Rolf, Samuel X. Qiu, Tran Dang Xuan, and Vincent Lebot. 2011. “Kava and Kava Hepatotoxicity: Requirements for Novel Experimental, Ethnobotanical and Clinical Studies Based on a Review of the Evidence.” *Phytotherapy Research: PTR* 25 (9): 1263–74. <https://doi.org/10.1002/ptr.3464>.

Teschke, Rolf, Jerome Sarris, Xaver Glass, and Johannes Schulze. 2011. “Kava, the Anxiolytic Herb: Back to Basics to Prevent Liver Injury?: Kava, back to Basics?” *British Journal of Clinical Pharmacology* 71 (3): 445–48. <https://doi.org/10.1111/j.1365-2125.2010.03775.x>.

Teschke, Rolf, Jerome Sarris, and Vincent Lebot. 2011. “Kava Hepatotoxicity Solution: A Six-Point Plan for New Kava Standardization.” *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 18 (2-3): 96–103. <https://doi.org/10.1016/j.phymed.2010.10.002>.

———. 2013. “Contaminant Hepatotoxins as Culprits for Kava Hepatotoxicity--Fact or Fiction?” *Phytotherapy Research: PTR* 27 (3): 472–74. <https://doi.org/10.1002/ptr.4729>.

Teschke, Rolf, Jerome Sarris, and Isaac Schweitzer. 2012. “Kava Hepatotoxicity in Traditional and Modern Use: The Presumed Pacific Kava Paradox Hypothesis Revisited.” *British Journal of Clinical Pharmacology* 73 (2): 170–74. <https://doi.org/10.1111/j.1365-2125.2011.04070.x>.

Teschke, Rolf, and Johannes Schulze. 2010. “Risk of Kava Hepatotoxicity and the FDA Consumer Advisory.” *JAMA: The Journal of the American Medical Association* 304 (19): 2174–75. <https://doi.org/10.1001/jama.2010.1689>.

Teschke, Rolf, Alexander Schwarzenboeck, and Karl-Heinz Hennermann. 2008. “Kava Hepatotoxicity: A Clinical Survey and Critical Analysis of 26 Suspected Cases.” *European Journal of Gastroenterology & Hepatology* 20 (12): 1182–93. <https://doi.org/10.1097/MEG.0b013e3283036768>.

Thomsen, Michael, Luis Vitetta, Matthias Schmidt, and Avni Sali. 2004. “Fatal Fulminant Hepatic Failure Induced by a Natural Therapy Containing Kava.” *The Medical Journal of Australia*. <https://doi.org/10.5694/j.1326-5377.2004.tb05875.x>.

Tugcu, Gulcin, Hasan Kirmızıbekmez, and Ahmet Aydın. 2020. “The Integrated Use of in Silico Methods for the Hepatotoxicity Potential of Piper Methysticum.” *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association* 145 (November): 111663. <https://doi.org/10.1016/j.fct.2020.111663>.

Yamazaki, Yuko, Hiroko Hashida, Anna Arita, Keiko Hamaguchi, and Fumio Shimura. 2008. “High Dose of Commercial Products of Kava (Piper Methysticum) Markedly Enhanced Hepatic Cytochrome P450 1A1

mRNA Expression with Liver Enlargement in Rats.” *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association* 46 (12): 3732–38.
<https://doi.org/10.1016/j.fct.2008.09.052>.

Yang, Xi, and William F. Salminen. 2011. “Kava Extract, an Herbal Alternative for Anxiety Relief, Potentiates Acetaminophen-Induced Cytotoxicity in Rat Hepatic Cells.” *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 18 (7): 592–600.
<https://doi.org/10.1016/j.phymed.2011.02.006>.